| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | chromatin binding | TCF4 HHEX PCGF2 CEBPB TOX NRL NELFA PATZ1 CHAF1A SREBF1 SREBF2 NR3C1 WAC SBNO1 EGR1 TOX3 KMT2A PKN1 CHD6 CABIN1 TOX2 MED12 | 2.22e-07 | 739 | 166 | 22 | GO:0003682 |
| GeneOntologyMolecularFunction | molecular adaptor activity | TCF4 ABL1 NELFA DTL GAS2 ICE1 TUT1 ZC3H18 NR3C1 MED13L SRCAP GRIP1 KSR1 MIDN TOB1 LAT AP2A1 BAZ2A ZMIZ2 PDE4DIP TOX3 JAZF1 PKN1 PLCB3 TAF6 TOX2 MED12 GAB1 KLHL17 | 2.33e-06 | 1356 | 166 | 29 | GO:0060090 |
| GeneOntologyMolecularFunction | DNA-binding transcription activator activity, RNA polymerase II-specific | TCF4 HHEX CEBPB NRL PATZ1 SOX30 MAFA SREBF1 NR4A1 NR3C1 RFX4 PRDM2 EGR1 SIX5 MAFB NPAS4 MAF | 4.50e-06 | 560 | 166 | 17 | GO:0001228 |
| GeneOntologyMolecularFunction | DNA-binding transcription activator activity | TCF4 HHEX CEBPB NRL PATZ1 SOX30 MAFA SREBF1 NR4A1 NR3C1 RFX4 PRDM2 EGR1 SIX5 MAFB NPAS4 MAF | 5.18e-06 | 566 | 166 | 17 | GO:0001216 |
| GeneOntologyMolecularFunction | kinase binding | ABL1 CEBPB TOM1L1 ZBTB4 SREBF1 CEACAM4 TNIP1 NR3C1 STK11IP FAM83C ZFP36 MAP3K1 KSR1 MIDN TOB1 LAT AP2A1 MICAL2 SCN5A PKN1 TNFAIP3 BORA RAD23A | 5.58e-06 | 969 | 166 | 23 | GO:0019900 |
| GeneOntologyMolecularFunction | cis-regulatory region sequence-specific DNA binding | TCF4 HHEX CEBPB NRL PATZ1 SOX30 MAFA ZBTB4 SREBF1 SREBF2 NR4A1 NR3C1 RFX4 MSX2 FOXB1 SLC2A4RG EGR1 ZFHX2 SIX5 DMRTB1 MAFB ZFHX3 MED12 ELL NPAS4 MAF | 1.82e-05 | 1271 | 166 | 26 | GO:0000987 |
| GeneOntologyMolecularFunction | protein-macromolecule adaptor activity | TCF4 ABL1 DTL GAS2 ICE1 TUT1 ZC3H18 NR3C1 MED13L SRCAP GRIP1 KSR1 TOB1 LAT AP2A1 BAZ2A ZMIZ2 TOX3 JAZF1 PKN1 TAF6 TOX2 MED12 GAB1 | 3.32e-05 | 1160 | 166 | 24 | GO:0030674 |
| GeneOntologyMolecularFunction | RNA polymerase II cis-regulatory region sequence-specific DNA binding | TCF4 HHEX CEBPB NRL PATZ1 SOX30 MAFA ZBTB4 SREBF1 SREBF2 NR4A1 NR3C1 RFX4 MSX2 FOXB1 SLC2A4RG EGR1 ZFHX2 SIX5 DMRTB1 MAFB ZFHX3 MED12 NPAS4 MAF | 3.61e-05 | 1244 | 166 | 25 | GO:0000978 |
| GeneOntologyMolecularFunction | RNA polymerase II transcription regulatory region sequence-specific DNA binding | TCF4 HHEX CEBPB NRL PATZ1 SOX30 MAFA ZBTB4 SREBF1 SREBF2 NR4A1 NR3C1 RFX4 PRDM2 MSX2 FOXB1 SLC2A4RG EGR1 ZFHX2 SIX5 DMRTB1 MAFB ZFHX3 MED12 NPAS4 NPAS1 MAF | 7.06e-05 | 1459 | 166 | 27 | GO:0000977 |
| GeneOntologyMolecularFunction | protein kinase binding | ABL1 TOM1L1 ZBTB4 SREBF1 CEACAM4 TNIP1 NR3C1 STK11IP FAM83C ZFP36 MAP3K1 KSR1 TOB1 LAT AP2A1 MICAL2 SCN5A PKN1 BORA | 1.23e-04 | 873 | 166 | 19 | GO:0019901 |
| GeneOntologyMolecularFunction | mitogen-activated protein kinase binding | 1.97e-04 | 35 | 166 | 4 | GO:0051019 | |
| GeneOntologyMolecularFunction | DNA-binding transcription factor activity, RNA polymerase II-specific | TCF4 HHEX CEBPB NRL PATZ1 SOX30 MAFA ZBTB4 SREBF1 SREBF2 NR4A1 NR3C1 RFX4 PRDM2 MSX2 FOXB1 EGR1 ZFHX2 SIX5 DMRTB1 MAFB ZFHX3 NPAS4 NPAS1 MAF | 2.67e-04 | 1412 | 166 | 25 | GO:0000981 |
| GeneOntologyMolecularFunction | DNA-binding transcription repressor activity, RNA polymerase II-specific | 3.56e-04 | 320 | 166 | 10 | GO:0001227 | |
| GeneOntologyMolecularFunction | extracellular matrix constituent, lubricant activity | 4.08e-04 | 4 | 166 | 2 | GO:0030197 | |
| GeneOntologyMolecularFunction | DNA-binding transcription repressor activity | 4.12e-04 | 326 | 166 | 10 | GO:0001217 | |
| GeneOntologyMolecularFunction | transcription coregulator activity | TCF4 ABL1 NR3C1 MED13L SRCAP TOB1 ZMIZ2 TOX3 JAZF1 PKN1 TAF6 TOX2 MED12 | 8.64e-04 | 562 | 166 | 13 | GO:0003712 |
| GeneOntologyMolecularFunction | transcription coactivator activity | 1.00e-03 | 303 | 166 | 9 | GO:0003713 | |
| GeneOntologyMolecularFunction | core promoter sequence-specific DNA binding | 1.13e-03 | 55 | 166 | 4 | GO:0001046 | |
| GeneOntologyMolecularFunction | polyubiquitin modification-dependent protein binding | 1.47e-03 | 59 | 166 | 4 | GO:0031593 | |
| GeneOntologyMolecularFunction | transcription factor binding | TCF4 HHEX CEBPB SREBF1 NR4A1 NR3C1 MSX2 BAZ2A KMT2A PKN1 CHD6 TAF6 BSN TOX2 MED12 | 1.58e-03 | 753 | 166 | 15 | GO:0008134 |
| GeneOntologyBiologicalProcess | positive regulation of transcription by RNA polymerase II | TET2 TCF4 HHEX ABL1 CEBPB TOX NRL NELFA PATZ1 SOX30 MAFA SREBF1 SREBF2 TNIP1 NR4A1 NR3C1 RFX4 MAP3K1 PRDM2 EGR1 MICAL2 ZMIZ2 TOX3 MEPCE KMT2A SIX5 MAFB ZFHX3 CHD6 TAF6 TOX2 MED12 ELL NPAS4 MAF | 1.20e-09 | 1390 | 166 | 35 | GO:0045944 |
| GeneOntologyBiologicalProcess | chromatin remodeling | TET2 PCGF2 CHAF1A NR3C1 SRCAP PRDM2 WAC EZHIP RSBN1 EGR1 BAZ2A KMT2A CENPV PKN1 CHD6 CABIN1 KAT14 INO80E | 3.08e-05 | 741 | 166 | 18 | GO:0006338 |
| GeneOntologyBiologicalProcess | negative regulation of transcription by RNA polymerase II | TCF4 HHEX PCGF2 CEBPB PATZ1 SOX30 ZBTB4 SREBF1 SREBF2 NR3C1 ZFP36 PRDM2 MSX2 ZNF469 EGR1 MEPCE JAZF1 MAFB ZFHX3 KAT14 NPAS1 MAF | 3.92e-05 | 1053 | 166 | 22 | GO:0000122 |
| GeneOntologyBiologicalProcess | negative regulation of DNA-templated transcription | TCF4 HHEX PCGF2 CEBPB NELFA PATZ1 SOX30 ZBTB4 SREBF1 SREBF2 NR3C1 ZFP36 PRDM2 MSX2 ZNF469 TOB1 EGR1 BAZ2A MEPCE JAZF1 SIX5 MAFB ZFHX3 KAT14 NPAS1 MAF | 5.37e-05 | 1399 | 166 | 26 | GO:0045892 |
| GeneOntologyBiologicalProcess | protein-DNA complex organization | TET2 TCF4 PCGF2 TOX CHAF1A NR3C1 SRCAP PRDM2 WAC EZHIP RSBN1 EGR1 BAZ2A KMT2A CENPV PKN1 CHD6 TAF6 CABIN1 KAT14 INO80E | 5.46e-05 | 999 | 166 | 21 | GO:0071824 |
| GeneOntologyBiologicalProcess | negative regulation of RNA biosynthetic process | TCF4 HHEX PCGF2 CEBPB NELFA PATZ1 SOX30 ZBTB4 SREBF1 SREBF2 NR3C1 ZFP36 PRDM2 MSX2 ZNF469 TOB1 EGR1 BAZ2A MEPCE JAZF1 SIX5 MAFB ZFHX3 KAT14 NPAS1 MAF | 6.33e-05 | 1413 | 166 | 26 | GO:1902679 |
| GeneOntologyBiologicalProcess | snRNA metabolic process | 1.12e-04 | 59 | 166 | 5 | GO:0016073 | |
| GeneOntologyBiologicalProcess | chromatin organization | TET2 PCGF2 TOX CHAF1A NR3C1 SRCAP PRDM2 WAC EZHIP RSBN1 EGR1 BAZ2A KMT2A CENPV PKN1 CHD6 CABIN1 KAT14 INO80E | 1.13e-04 | 896 | 166 | 19 | GO:0006325 |
| GeneOntologyCellularComponent | Golgi lumen | 1.47e-08 | 109 | 164 | 10 | GO:0005796 | |
| GeneOntologyCellularComponent | chromatin | TCF4 HHEX PCGF2 CEBPB NRL CHAF1A SOX30 MAFA SREBF1 SREBF2 ICE1 NR4A1 NR3C1 SRCAP RFX4 MSX2 FOXB1 EGR1 BAZ2A ZMIZ2 ZFHX2 SIX5 DMRTB1 MAFB ZFHX3 CHD6 TAF6 KAT14 ELL NPAS4 NPAS1 MAF INO80E | 3.99e-08 | 1480 | 164 | 33 | GO:0000785 |
| GeneOntologyCellularComponent | nuclear protein-containing complex | TCF4 PCGF2 CEBPB ACD NELFA UBQLN4 ICE1 TUT1 MED13L SRCAP POM121C WAC INTS5 LAT BAZ2A AMOTL1 MEPCE DOCK7 SUGP1 KMT2A MAFB TAF6 POM121B MED12 ELL MAF INO80E | 9.25e-06 | 1377 | 164 | 27 | GO:0140513 |
| GeneOntologyCellularComponent | nuclear body | HHEX PCGF2 ABL1 ACD NELFA ZBTB4 ANKS1B ICE1 TUT1 ZC3H18 NR3C1 SRCAP WAC MSX2 SLC2A4RG BAZ2A SIMC1 ZFHX3 ELL | 8.95e-05 | 903 | 164 | 19 | GO:0016604 |
| GeneOntologyCellularComponent | mucus layer | 1.83e-04 | 3 | 164 | 2 | GO:0070701 | |
| GeneOntologyCellularComponent | histone locus body | 3.63e-04 | 4 | 164 | 2 | GO:0035363 | |
| HumanPheno | Abnormal hair morphology | TCF4 PCGF2 ABL1 ACD UBE4B NELFA SREBF1 TNIP1 SEC31A NR3C1 MED13L SRCAP PXK MAP3K1 WAC GRIP1 ZNF469 MEGF8 DOCK7 JAZF1 KMT2A MAFB CHD6 TNFAIP3 HERC1 TAF6 MED12 MAF | 1.58e-05 | 1424 | 49 | 28 | HP:0001595 |
| HumanPheno | Dilatation of renal calices | 1.64e-05 | 6 | 49 | 3 | HP:0100581 | |
| HumanPheno | Abnormal renal calyx morphology | 1.64e-05 | 6 | 49 | 3 | HP:0011130 | |
| HumanPheno | Abnormal scalp morphology | PCGF2 ACD NELFA NR3C1 MED13L SRCAP MSX2 MEGF8 DOCK7 KMT2A MAFB TAF6 MED12 MAF | 5.39e-05 | 450 | 49 | 14 | HP:0001965 |
| HumanPheno | Abnormal pigmentation of the oral mucosa | 5.48e-05 | 44 | 49 | 5 | HP:0100669 | |
| HumanPheno | Abnormality of the scalp hair | PCGF2 ACD NELFA NR3C1 MED13L SRCAP MEGF8 DOCK7 KMT2A MAFB TAF6 MED12 MAF | 1.54e-04 | 433 | 49 | 13 | HP:0100037 |
| HumanPheno | Anti-complement component C1q antibody positivity | 1.72e-04 | 30 | 49 | 4 | HP:0034077 | |
| HumanPheno | Anti-ribosome Po antibody positivity | 1.72e-04 | 30 | 49 | 4 | HP:0034076 | |
| HumanPheno | Anti-phosphatidic acid antibody positivity | 1.72e-04 | 30 | 49 | 4 | HP:0034096 | |
| HumanPheno | Anti-Ro52/TRIM21 antibody positivity | 1.72e-04 | 30 | 49 | 4 | HP:0034093 | |
| HumanPheno | Anti-La/SS-B antibody positivity | 1.72e-04 | 30 | 49 | 4 | HP:0032235 | |
| HumanPheno | Anti-nucleoporin 62 antibody positivity | 1.72e-04 | 30 | 49 | 4 | HP:0033556 | |
| HumanPheno | Anti-titin antibody positivity | 1.72e-04 | 30 | 49 | 4 | HP:5000038 | |
| HumanPheno | Pyuria | 1.96e-04 | 31 | 49 | 4 | HP:0012085 | |
| HumanPheno | Cheilitis | 2.09e-04 | 58 | 49 | 5 | HP:0100825 | |
| HumanPheno | Lupus nephritis | 2.23e-04 | 32 | 49 | 4 | HP:0033726 | |
| HumanPheno | Anti-U1 ribonucleoprotein antibody positivity | 2.23e-04 | 32 | 49 | 4 | HP:0033028 | |
| HumanPheno | Anti-Sm antibody positivity | 2.23e-04 | 32 | 49 | 4 | HP:0033040 | |
| HumanPheno | Extractable nuclear antigen positivity | 2.84e-04 | 34 | 49 | 4 | HP:0033476 | |
| HumanPheno | Anti-dsDNA antibody positivity | 2.84e-04 | 34 | 49 | 4 | HP:0020151 | |
| HumanPheno | Decreased circulating complement C4 concentration | 3.18e-04 | 35 | 49 | 4 | HP:0045042 | |
| Domain | Maf_N | 5.45e-09 | 4 | 162 | 4 | PF08383 | |
| Domain | Maf_TF_N | 5.45e-09 | 4 | 162 | 4 | IPR013592 | |
| Domain | Transciption_factor_Maf_fam | 1.87e-07 | 7 | 162 | 4 | IPR024874 | |
| Domain | SEA | 1.37e-06 | 23 | 162 | 5 | PS50024 | |
| Domain | SEA_dom | 1.37e-06 | 23 | 162 | 5 | IPR000082 | |
| Domain | bZIP_Maf | 3.67e-06 | 13 | 162 | 4 | IPR004826 | |
| Domain | bZIP_Maf | 3.67e-06 | 13 | 162 | 4 | PF03131 | |
| Domain | SEA | 5.10e-06 | 14 | 162 | 4 | SM00200 | |
| Domain | - | 9.15e-06 | 16 | 162 | 4 | 1.10.880.10 | |
| Domain | SEA | 3.53e-05 | 22 | 162 | 4 | PF01390 | |
| Domain | AT_hook | 8.19e-05 | 27 | 162 | 4 | SM00384 | |
| Domain | AT_hook_DNA-bd_motif | 8.19e-05 | 27 | 162 | 4 | IPR017956 | |
| Domain | BRLZ | 8.63e-05 | 52 | 162 | 5 | SM00338 | |
| Domain | BZIP_BASIC | 9.46e-05 | 53 | 162 | 5 | PS00036 | |
| Domain | BZIP | 9.46e-05 | 53 | 162 | 5 | PS50217 | |
| Domain | bZIP | 1.04e-04 | 54 | 162 | 5 | IPR004827 | |
| Domain | C8 | 1.33e-04 | 12 | 162 | 3 | PF08742 | |
| Domain | TIL | 1.33e-04 | 12 | 162 | 3 | PF01826 | |
| Domain | Unchr_dom_Cys-rich | 1.72e-04 | 13 | 162 | 3 | IPR014853 | |
| Domain | C8 | 1.72e-04 | 13 | 162 | 3 | SM00832 | |
| Domain | TIL_dom | 2.17e-04 | 14 | 162 | 3 | IPR002919 | |
| Domain | TF_DNA-bd | 2.88e-04 | 37 | 162 | 4 | IPR008917 | |
| Domain | VWF_type-D | 3.30e-04 | 16 | 162 | 3 | IPR001846 | |
| Domain | VWFD | 3.30e-04 | 16 | 162 | 3 | PS51233 | |
| Domain | AT_hook | 3.30e-04 | 16 | 162 | 3 | PF02178 | |
| Domain | VWD | 3.30e-04 | 16 | 162 | 3 | SM00216 | |
| Domain | VWD | 3.30e-04 | 16 | 162 | 3 | PF00094 | |
| Domain | VWC_out | 5.60e-04 | 19 | 162 | 3 | SM00215 | |
| Domain | CT | 8.74e-04 | 22 | 162 | 3 | SM00041 | |
| Domain | PAS_fold_3 | 9.99e-04 | 23 | 162 | 3 | IPR013655 | |
| Domain | PAS_3 | 9.99e-04 | 23 | 162 | 3 | PF08447 | |
| Domain | WxxW_domain | 1.10e-03 | 6 | 162 | 2 | IPR025155 | |
| Domain | Mucin2_WxxW | 1.10e-03 | 6 | 162 | 2 | PF13330 | |
| Domain | PAS-assoc_C | 1.13e-03 | 24 | 162 | 3 | IPR000700 | |
| Domain | HMG_box | 1.15e-03 | 53 | 162 | 4 | PF00505 | |
| Domain | HMG_BOX_2 | 1.23e-03 | 54 | 162 | 4 | PS50118 | |
| Domain | HMG | 1.23e-03 | 54 | 162 | 4 | SM00398 | |
| Domain | Cys_knot_C | 1.28e-03 | 25 | 162 | 3 | IPR006207 | |
| Domain | CTCK_2 | 1.28e-03 | 25 | 162 | 3 | PS01225 | |
| Domain | - | 1.32e-03 | 55 | 162 | 4 | 1.10.30.10 | |
| Domain | PAC | 1.44e-03 | 26 | 162 | 3 | PS50113 | |
| Domain | Znf_U1 | 1.98e-03 | 29 | 162 | 3 | IPR003604 | |
| Domain | ZnF_U1 | 1.98e-03 | 29 | 162 | 3 | SM00451 | |
| Domain | UBA | 2.19e-03 | 30 | 162 | 3 | SM00165 | |
| Pathway | REACTOME_DEFECTIVE_GALNT3_CAUSES_HFTC | 2.02e-11 | 16 | 114 | 7 | M27410 | |
| Pathway | REACTOME_DEFECTIVE_C1GALT1C1_CAUSES_TNPS | 3.42e-11 | 17 | 114 | 7 | M27412 | |
| Pathway | REACTOME_TERMINATION_OF_O_GLYCAN_BIOSYNTHESIS | 4.14e-10 | 23 | 114 | 7 | M556 | |
| Pathway | REACTOME_DECTIN_2_FAMILY | 1.09e-09 | 26 | 114 | 7 | M27483 | |
| Pathway | REACTOME_TERMINATION_OF_O_GLYCAN_BIOSYNTHESIS | 5.81e-07 | 21 | 114 | 5 | MM15706 | |
| Pathway | REACTOME_O_LINKED_GLYCOSYLATION_OF_MUCINS | 6.40e-07 | 62 | 114 | 7 | M546 | |
| Pathway | REACTOME_DISEASES_ASSOCIATED_WITH_O_GLYCOSYLATION_OF_PROTEINS | 1.21e-06 | 68 | 114 | 7 | M27303 | |
| Pathway | REACTOME_DISEASES_OF_GLYCOSYLATION | 2.05e-05 | 143 | 114 | 8 | M27275 | |
| Pathway | REACTOME_O_LINKED_GLYCOSYLATION | 3.19e-05 | 111 | 114 | 7 | M27416 | |
| Pathway | REACTOME_O_LINKED_GLYCOSYLATION_OF_MUCINS | 1.21e-04 | 60 | 114 | 5 | MM15636 | |
| Pathway | REACTOME_C_TYPE_LECTIN_RECEPTORS_CLRS | 1.39e-04 | 140 | 114 | 7 | M27484 | |
| Pubmed | A dual-activity topoisomerase complex regulates mRNA translation and turnover. | ABL1 CEBPB UBE4B ZBTB4 SREBF1 ADGRL1 ICE1 LRRK1 MED13L SRCAP POM121C STK11IP CCDC88C MSX2 INTS5 HEG1 ARHGEF40 AATK SLC2A4RG AP2A1 MEGF8 ZMIZ2 SCN5A TIGD3 CENPV DISP2 PKN1 TNFAIP3 HERC1 CABIN1 MED12 ELL KLHL17 | 3.42e-17 | 1105 | 167 | 33 | 35748872 |
| Pubmed | A census of human transcription factors: function, expression and evolution. | TCF4 HHEX CEBPB NRL PATZ1 SOX30 MAFA ZBTB4 SREBF1 SREBF2 NR4A1 NR3C1 RFX4 PRDM2 MSX2 FOXB1 EGR1 TOX3 JAZF1 ZFHX2 KMT2A SIX5 DMRTB1 MAFB ZFHX3 TOX2 NPAS1 MAF | 5.10e-15 | 908 | 167 | 28 | 19274049 |
| Pubmed | Mucin gene expression in human laryngeal epithelia: effect of laryngopharyngeal reflux. | 1.00e-14 | 18 | 167 | 8 | 18834073 | |
| Pubmed | A central chaperone-like role for 14-3-3 proteins in human cells. | TET2 ABL1 UBAP2 TRPM7 KIF26B PATZ1 PAK5 DTL PITPNC1 PPP4R4 GRIP1 USP31 CCDC88C KSR1 MEGF8 PRRC2C STARD9 MEPCE DOCK7 KMT2A TNFAIP3 WNK4 GAB1 | 3.09e-11 | 861 | 167 | 23 | 36931259 |
| Pubmed | UBE4B ADGRL1 MED13L USP31 RSBN1 MEGF8 MEGF9 BAZ2A PRRC2C STARD9 ZFR2 PDE4DIP DOCK7 DISP2 CHD6 | 1.43e-09 | 407 | 167 | 15 | 12693553 | |
| Pubmed | 7.63e-09 | 6 | 167 | 4 | 19110483 | ||
| Pubmed | TCF4 HHEX PCGF2 TOX RTN4 SREBF1 SREBF2 TUT1 NR4A1 NR3C1 MSX2 BAZ2A ZMIZ2 ZFHX2 KMT2A SIX5 ZFHX3 NPAS4 | 1.09e-08 | 709 | 167 | 18 | 22988430 | |
| Pubmed | H4K20me0 recognition by BRCA1-BARD1 directs homologous recombination to sister chromatids. | ATXN7L2 CEBPB ACD PATZ1 CHAF1A UBQLN4 SREBF1 ZC3H18 NR4A1 SRCAP POM121C PRDM2 WAC INTS5 AP2A1 BAZ2A JAZF1 KMT2A CENPV CHD6 TAF6 CABIN1 KAT14 INO80E | 1.56e-08 | 1294 | 167 | 24 | 30804502 |
| Pubmed | ATXN7L2 ARHGAP10 PATZ1 CHAF1A ZC3H18 SRCAP POM121C RSBN1 KSR1 ZNF469 ARHGEF40 MCTP1 BAZ2A SCN5A MEPCE JAZF1 ZFHX3 TAF6 PDLIM2 KAT14 INO80E | 1.05e-07 | 1116 | 167 | 21 | 31753913 | |
| Pubmed | Expression of mucin 3 and mucin 5AC in arthritic synovial tissue. | 1.09e-07 | 3 | 167 | 3 | 18163520 | |
| Pubmed | 1.09e-07 | 3 | 167 | 3 | 27659348 | ||
| Pubmed | 1.09e-07 | 3 | 167 | 3 | 18825309 | ||
| Pubmed | 1.09e-07 | 3 | 167 | 3 | 10512748 | ||
| Pubmed | 1.09e-07 | 3 | 167 | 3 | 18300795 | ||
| Pubmed | KIF26B CHAF1A PAK5 TOM1L1 SREBF2 ADGRL1 MUC12 SEC31A POM121C EGR1 SIMC1 CHD6 TNFAIP3 GAB1 | 1.10e-07 | 486 | 167 | 14 | 20936779 | |
| Pubmed | ATXN7L2 ACD UBQLN4 SREBF1 TNIP1 NR4A1 WAC GORASP2 MEGF8 PDE4DIP SIX5 DMRTB1 CHD6 NOVA1 RAD23A | 2.80e-07 | 608 | 167 | 15 | 16713569 | |
| Pubmed | TET2 TCF4 UBAP2 ATXN7L2 TNIP1 ZC3H18 SRCAP POM121C PRDM2 RSBN1 MIDN PRRC2C ZMIZ2 SUGP1 KMT2A SIX5 ZFHX3 CHD6 HERC1 TAF6 CABIN1 KAT14 INO80E | 3.97e-07 | 1429 | 167 | 23 | 35140242 | |
| Pubmed | TCEA3 TCF4 HHEX TOX PATZ1 SREBF1 NR3C1 SRCAP ZFP36 KRBA1 EGR1 BAZ2A ZMIZ2 TOX3 JAZF1 ZFHX3 TAF6 | 4.08e-07 | 808 | 167 | 17 | 20412781 | |
| Pubmed | Impact of cytosine methylation on DNA binding specificities of human transcription factors. | TCF4 CEBPB NRL SOX30 MAFA SREBF1 SREBF2 NR4A1 NR3C1 RFX4 MSX2 FOXB1 EGR1 MAF | 4.30e-07 | 544 | 167 | 14 | 28473536 |
| Pubmed | Granuphilin is activated by SREBP-1c and involved in impaired insulin secretion in diabetic mice. | 4.33e-07 | 4 | 167 | 3 | 16890542 | |
| Pubmed | 4.33e-07 | 4 | 167 | 3 | 22496870 | ||
| Pubmed | 4.33e-07 | 4 | 167 | 3 | 23807779 | ||
| Pubmed | Inhibition of the deubiquitinase USP5 leads to c-Maf protein degradation and myeloma cell apoptosis. | 4.33e-07 | 4 | 167 | 3 | 28933784 | |
| Pubmed | 4.33e-07 | 4 | 167 | 3 | 33154304 | ||
| Pubmed | Gastric mucin expression in first-degree relatives of gastric cancer patients. | 4.33e-07 | 4 | 167 | 3 | 24901817 | |
| Pubmed | 4.33e-07 | 4 | 167 | 3 | 36367122 | ||
| Pubmed | 4.33e-07 | 4 | 167 | 3 | 17471237 | ||
| Pubmed | 4.33e-07 | 4 | 167 | 3 | 14984930 | ||
| Pubmed | Effects of the Helicobacter pylori Virulence Factor CagA and Ammonium Ion on Mucins in AGS Cells. | 4.33e-07 | 4 | 167 | 3 | 29869461 | |
| Pubmed | Mucins in neoplastic spectrum of colorectal polyps: can they provide predictions? | 4.33e-07 | 4 | 167 | 3 | 20929551 | |
| Pubmed | MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: expression profiles and clinical significance. | 4.33e-07 | 4 | 167 | 3 | 27298226 | |
| Pubmed | Mucin expression profile in Barrett's, dysplasia, adenocarcinoma sequence in the esophagus. | 4.33e-07 | 4 | 167 | 3 | 17401217 | |
| Pubmed | 4.33e-07 | 4 | 167 | 3 | 12676567 | ||
| Pubmed | 4.33e-07 | 4 | 167 | 3 | 25298197 | ||
| Pubmed | 6.43e-07 | 263 | 167 | 10 | 20932939 | ||
| Pubmed | TET2 PCGF2 UBE4B TRPM7 ZBTB4 UBQLN4 ANKS1B SH3GLB2 SEC31A MED13L ZFP36 WAC GORASP2 AP2A1 MEGF9 SBNO1 MICAL2 PDE4DIP CHD6 TAF6 CABIN1 | 1.04e-06 | 1285 | 167 | 21 | 35914814 | |
| Pubmed | 1.08e-06 | 5 | 167 | 3 | 12507512 | ||
| Pubmed | 1.08e-06 | 5 | 167 | 3 | 12135769 | ||
| Pubmed | 1.08e-06 | 5 | 167 | 3 | 12917329 | ||
| Pubmed | MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer. | 1.08e-06 | 5 | 167 | 3 | 16475027 | |
| Pubmed | 1.08e-06 | 5 | 167 | 3 | 22261707 | ||
| Pubmed | An atlas of combinatorial transcriptional regulation in mouse and man. | TCF4 HHEX PCGF2 NELFA CHAF1A SREBF1 SREBF2 NR3C1 RFX4 ZFP36 MSX2 FOXB1 EGR1 TOX3 MAFB TNFAIP3 ELL | 1.25e-06 | 877 | 167 | 17 | 20211142 |
| Pubmed | UBE4B TRPM7 NELFA CHAF1A DTL SREBF1 SREBF2 ZC3H18 MUC12 SEC31A MED13L PPP4R4 WAC SBNO1 SUGP1 KMT2A TAF6 USP1 KAT14 MED12 ELL | 1.74e-06 | 1327 | 167 | 21 | 32694731 | |
| Pubmed | An ARC/Mediator subunit required for SREBP control of cholesterol and lipid homeostasis. | 1.88e-06 | 19 | 167 | 4 | 16799563 | |
| Pubmed | Tumor promoter-inducible genes are differentially expressed in the developing mouse. | 2.15e-06 | 6 | 167 | 3 | 3185562 | |
| Pubmed | 2.15e-06 | 6 | 167 | 3 | 16386788 | ||
| Pubmed | 2.15e-06 | 6 | 167 | 3 | 17982272 | ||
| Pubmed | Role of large MAF transcription factors in the mouse endocrine pancreas. | 2.15e-06 | 6 | 167 | 3 | 25912440 | |
| Pubmed | Pyk2 suppresses contextual fear memory in an autophosphorylation-independent manner. | 2.15e-06 | 6 | 167 | 3 | 34529077 | |
| Pubmed | 2.88e-06 | 21 | 167 | 4 | 29324782 | ||
| Pubmed | 3.34e-06 | 130 | 167 | 7 | 19386638 | ||
| Pubmed | Neither MafA/L-Maf nor MafB is essential for lens development in mice. | 3.75e-06 | 7 | 167 | 3 | 19624757 | |
| Pubmed | 4.63e-06 | 257 | 167 | 9 | 30945288 | ||
| Pubmed | TET2 UBQLN4 TNIP1 ICE1 PRDM2 ZMIZ2 DOCK7 ZFHX3 CHD6 KAT14 MED12 | 6.26e-06 | 418 | 167 | 11 | 34709266 | |
| Pubmed | Menin and Menin-Associated Proteins Coregulate Cancer Energy Metabolism. | UBE4B ZC3H18 SRCAP POM121C WAC RSBN1 SBNO1 BAZ2A KMT2A MED12 | 6.53e-06 | 341 | 167 | 10 | 32971831 |
| Pubmed | Defining the human deubiquitinating enzyme interaction landscape. | UBAP2 ATXN7L2 DTL ICE1 TUT1 ZC3H18 LAT AMOTL1 KCTD3 MEPCE DOCK7 TNFAIP3 USP1 ELL BORA RAD23A INO80E | 7.64e-06 | 1005 | 167 | 17 | 19615732 |
| Pubmed | Proteome-scale mapping of binding sites in the unstructured regions of the human proteome. | UBAP2 POM121C MAP3K1 ZNF469 AATK TOB1 EGR1 ZMIZ2 BSN WNK4 GAB1 | 8.16e-06 | 430 | 167 | 11 | 35044719 |
| Pubmed | 8.26e-06 | 27 | 167 | 4 | 23740937 | ||
| Pubmed | Interaction network of human early embryonic transcription factors. | 8.40e-06 | 351 | 167 | 10 | 38297188 | |
| Pubmed | A directed protein interaction network for investigating intracellular signal transduction. | TCF4 RTN4 TOM1L1 UBQLN4 ICE1 SEC31A NR4A1 NR3C1 CCDC88C GORASP2 MIDN SNCAIP SIMC1 PDE4DIP DOCK7 PKN1 NOVA1 RAD23A | 8.57e-06 | 1124 | 167 | 18 | 21900206 |
| Pubmed | MafB-restricted local monocyte proliferation precedes lung interstitial macrophage differentiation. | 8.94e-06 | 9 | 167 | 3 | 36928411 | |
| Pubmed | Reexpression of oncoprotein MafB in proliferative β-cells and Men1 insulinomas in mouse. | 8.94e-06 | 9 | 167 | 3 | 22120711 | |
| Pubmed | Transcriptome analysis of mouse stem cells and early embryos. | ABL1 ARHGAP10 CEACAM4 NR3C1 SRCAP WAC PDE4DIP CHD6 CABIN1 KLHL17 | 1.12e-05 | 363 | 167 | 10 | 14691545 |
| Pubmed | Regulation of lens fiber cell differentiation by transcription factor c-Maf. | 1.27e-05 | 10 | 167 | 3 | 10383433 | |
| Pubmed | Shotgun sequencing of the human transcriptome with ORF expressed sequence tags. | UBAP2 CEACAM4 MUC16 SEC31A POM121C PRDM2 PDE4DIP ZFHX2 MUC2 MUC3A MAST3 NOVA1 | 1.61e-05 | 552 | 167 | 12 | 10737800 |
| Pubmed | 2.29e-05 | 2 | 167 | 2 | 27614840 | ||
| Pubmed | 2.29e-05 | 2 | 167 | 2 | 12965196 | ||
| Pubmed | 2.29e-05 | 2 | 167 | 2 | 15062879 | ||
| Pubmed | 2.29e-05 | 2 | 167 | 2 | 20453467 | ||
| Pubmed | 2.29e-05 | 2 | 167 | 2 | 22220206 | ||
| Pubmed | 2.29e-05 | 2 | 167 | 2 | 28367087 | ||
| Pubmed | 2.29e-05 | 2 | 167 | 2 | 16879892 | ||
| Pubmed | SREBP transcription factors: master regulators of lipid homeostasis. | 2.29e-05 | 2 | 167 | 2 | 15589694 | |
| Pubmed | JAZF1 ameliorates age and diet-associated hepatic steatosis through SREBP-1c -dependent mechanism. | 2.29e-05 | 2 | 167 | 2 | 30154417 | |
| Pubmed | 2.29e-05 | 2 | 167 | 2 | 16141315 | ||
| Pubmed | 2.29e-05 | 2 | 167 | 2 | 28321513 | ||
| Pubmed | 2.29e-05 | 2 | 167 | 2 | 10585467 | ||
| Pubmed | 2.29e-05 | 2 | 167 | 2 | 33477751 | ||
| Pubmed | Large Maf transcription factor family is a major regulator of fast type IIb myofiber determination. | 2.29e-05 | 2 | 167 | 2 | 36952339 | |
| Pubmed | 2.29e-05 | 2 | 167 | 2 | 15249232 | ||
| Pubmed | Multiple transcripts of MUC3: evidence for two genes, MUC3A and MUC3B. | 2.29e-05 | 2 | 167 | 2 | 10973822 | |
| Pubmed | 2.29e-05 | 2 | 167 | 2 | 30504806 | ||
| Pubmed | 2.29e-05 | 2 | 167 | 2 | 17321686 | ||
| Pubmed | Altered expression of MUC2 and MUC5AC in progression of colorectal carcinoma. | 2.29e-05 | 2 | 167 | 2 | 20731025 | |
| Pubmed | 2.29e-05 | 2 | 167 | 2 | 37467321 | ||
| Pubmed | 2.29e-05 | 2 | 167 | 2 | 32764399 | ||
| Pubmed | The complete genomic organization of the human MUC6 and MUC2 mucin genes. | 2.29e-05 | 2 | 167 | 2 | 15081123 | |
| Pubmed | High-fat Diet Alters the Glycosylation Patterns of Duodenal Mucins in a Murine Model. | 2.29e-05 | 2 | 167 | 2 | 32141795 | |
| Pubmed | MUC2 and MUC6 apomucins expression in human gastric neoplasm: an immunohistochemical analysis. | 2.29e-05 | 2 | 167 | 2 | 20878553 | |
| Pubmed | 2.29e-05 | 2 | 167 | 2 | 38720423 | ||
| Pubmed | 2.29e-05 | 2 | 167 | 2 | 18936756 | ||
| Pubmed | 2.29e-05 | 2 | 167 | 2 | 29449559 | ||
| Pubmed | 2.29e-05 | 2 | 167 | 2 | 8402897 | ||
| Pubmed | 2.29e-05 | 2 | 167 | 2 | 31490983 | ||
| Pubmed | 2.29e-05 | 2 | 167 | 2 | 23665916 | ||
| Pubmed | 2.29e-05 | 2 | 167 | 2 | 23832517 | ||
| Pubmed | 2.29e-05 | 2 | 167 | 2 | 23832516 | ||
| Pubmed | 2.29e-05 | 2 | 167 | 2 | 20060689 | ||
| Pubmed | 2.29e-05 | 2 | 167 | 2 | 23000402 | ||
| Pubmed | 2.29e-05 | 2 | 167 | 2 | 11988092 | ||
| Interaction | TOP3B interactions | ABL1 UBAP2 CEBPB UBE4B ZBTB4 SREBF1 ADGRL1 ICE1 LRRK1 MED13L SRCAP POM121C STK11IP ZFP36 CCDC88C MSX2 GORASP2 INTS5 HEG1 ARHGEF40 AATK SLC2A4RG AP2A1 MEGF8 ZMIZ2 SCN5A TIGD3 CENPV DISP2 PKN1 TNFAIP3 HERC1 CABIN1 MED12 ELL KLHL17 | 2.18e-09 | 1470 | 165 | 36 | int:TOP3B |
| Interaction | YWHAZ interactions | TET2 ABL1 CEBPB TRPM7 KIF26B NELFA CHAF1A PAK5 DTL TNIP1 ZC3H18 NR4A1 PITPNC1 STAC MAP3K1 PPP4R4 GRIP1 USP31 CCDC88C MSX2 KSR1 MCTP1 STARD9 AMOTL1 SIMC1 MEPCE DOCK7 KMT2A TNFAIP3 GAB1 MAST3 | 8.93e-08 | 1319 | 165 | 31 | int:YWHAZ |
| Interaction | YWHAH interactions | TET2 ABL1 UBAP2 CEBPB TRPM7 KIF26B PAK5 DTL NR3C1 PITPNC1 ZFP36 PPP4R4 GRIP1 USP31 CCDC88C KSR1 SNCAIP MEGF8 PRRC2C STARD9 MEPCE DOCK7 KMT2A TNFAIP3 HERC1 GAB1 MAST3 | 3.06e-07 | 1102 | 165 | 27 | int:YWHAH |
| Interaction | YWHAQ interactions | TET2 ABL1 UBAP2 CEBPB TRPM7 ARHGAP10 KIF26B CHAF1A PAK5 DTL UBQLN4 TUT1 ZFP36 MAP3K1 PPP4R4 GRIP1 USP31 CCDC88C KSR1 STARD9 MEPCE DOCK7 KMT2A TNFAIP3 CABIN1 WNK4 GAB1 | 4.06e-07 | 1118 | 165 | 27 | int:YWHAQ |
| Interaction | YWHAE interactions | TET2 ABL1 CEBPB ACD TRPM7 KIF26B CHAF1A PAK5 DTL TNIP1 ZC3H18 STAC MAP3K1 PPP4R4 GRIP1 USP31 CCDC88C MSX2 KSR1 MIDN AMOTL1 MEPCE DOCK7 KMT2A TNFAIP3 GAB1 MAST3 RAD23A | 1.19e-06 | 1256 | 165 | 28 | int:YWHAE |
| Interaction | TLE3 interactions | TET2 TCF4 HHEX CEBPB ZBTB4 NR3C1 WAC FOXB1 EGR1 ZMIZ2 AGFG2 KMT2A ZFHX3 CHD6 | 2.75e-06 | 376 | 165 | 14 | int:TLE3 |
| Interaction | YWHAB interactions | TET2 ABL1 CEBPB TRPM7 KIF26B NELFA CHAF1A PAK5 DTL PITPNC1 STAC ZFP36 PPP4R4 GRIP1 USP31 CCDC88C KSR1 STARD9 MEPCE DOCK7 KMT2A TNFAIP3 GAB1 MAST3 | 2.75e-06 | 1014 | 165 | 24 | int:YWHAB |
| Interaction | YWHAG interactions | TET2 ABL1 UBAP2 CEBPB TRPM7 KIF26B CHAF1A PAK5 DTL PITPNC1 ZFP36 MAP3K1 PPP4R4 GRIP1 USP31 CCDC88C KSR1 PRRC2C STARD9 SIMC1 MEPCE DOCK7 KMT2A MAFB TNFAIP3 GAB1 MAST3 | 3.33e-06 | 1248 | 165 | 27 | int:YWHAG |
| Interaction | MAPK1 interactions | CEBPB NRL UBE4B MAFA SREBF1 SREBF2 TNIP1 NR4A1 NR3C1 MAP3K1 MSX2 KSR1 GORASP2 TOB1 MAFB GAB1 | 1.04e-05 | 543 | 165 | 16 | int:MAPK1 |
| Interaction | SFN interactions | TET2 ABL1 CEBPB TRPM7 KIF26B DTL ZC3H18 NR3C1 ZFP36 PPP4R4 GRIP1 USP31 CCDC88C KSR1 PRRC2C DOCK7 KMT2A GAB1 | 1.56e-05 | 692 | 165 | 18 | int:SFN |
| Interaction | TLE5 interactions | TCF4 HHEX OXER1 UBAP2 PATZ1 MSX2 GORASP2 SNCAIP TOX3 TIGD3 DMRTB1 ZFHX3 NPAS1 INO80E | 1.77e-05 | 443 | 165 | 14 | int:TLE5 |
| Interaction | MED26 interactions | 2.85e-05 | 107 | 165 | 7 | int:MED26 | |
| Interaction | TRAF2 interactions | PCGF2 KIF26B SOX30 UBQLN4 TNIP1 NR4A1 NR3C1 LRIT3 ZFP36 MAP3K1 USP31 GORASP2 AP2A1 PKN1 TNFAIP3 RAD23A | 3.74e-05 | 603 | 165 | 16 | int:TRAF2 |
| Interaction | ASF1A interactions | 4.05e-05 | 249 | 165 | 10 | int:ASF1A | |
| Interaction | ACAD11 interactions | 5.53e-05 | 161 | 165 | 8 | int:ACAD11 | |
| Interaction | PSMA7 interactions | 6.21e-05 | 262 | 165 | 10 | int:PSMA7 | |
| Interaction | SAMD14 interactions | 6.66e-05 | 2 | 165 | 2 | int:SAMD14 | |
| Interaction | HDAC1 interactions | TET2 CEBPB TRPM7 CHAF1A UBQLN4 SREBF1 TNIP1 NR4A1 NR3C1 ZFP36 GRIP1 MSX2 BAZ2A ZMIZ2 DOCK7 KMT2A ZFHX3 TAF6 CABIN1 KAT14 MED12 ELL | 1.06e-04 | 1108 | 165 | 22 | int:HDAC1 |
| Cytoband | Ensembl 112 genes in cytogenetic band chr7q22 | 1.60e-04 | 219 | 167 | 6 | chr7q22 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr19p13 | PRR36 CHAF1A MUC16 ADGRL1 MIDN ZFR2 SUGP1 PKN1 ELL MAST3 RAD23A | 1.76e-04 | 797 | 167 | 11 | chr19p13 |
| Cytoband | 7q22 | 3.63e-04 | 38 | 167 | 3 | 7q22 | |
| Cytoband | 7q22.1 | 7.99e-04 | 113 | 167 | 4 | 7q22.1 | |
| GeneFamily | CD molecules|Mucins | 1.75e-15 | 21 | 107 | 9 | 648 | |
| GeneFamily | Basic leucine zipper proteins | 1.02e-05 | 49 | 107 | 5 | 506 | |
| GeneFamily | Basic helix-loop-helix proteins | 4.94e-04 | 110 | 107 | 5 | 420 | |
| Coexpression | MANNO_MIDBRAIN_NEUROTYPES_HGABA | RTN4 PAK5 ANKS1B ADGRL1 FNBP1L MED13L PITPNC1 PXK PRDM2 GRIP1 AATK NALF1 MEGF9 PDE4DIP TOX3 ZFHX2 SDC3 ZFHX3 HERC1 BSN SAMD14 MUC2 TOX2 NOVA1 | 1.39e-07 | 1106 | 166 | 24 | M39071 |
| Coexpression | NABA_ECM_AFFILIATED | 1.41e-07 | 170 | 166 | 10 | M5880 | |
| Coexpression | GSE27241_WT_VS_RORGT_KO_TH17_POLARIZED_CD4_TCELL_TREATED_WITH_DIGOXIN_UP | TET2 UBAP2 UBE4B PITPNC1 SBNO1 BAZ2A PRRC2C NEURL1B HERC1 TOX2 | 2.39e-07 | 180 | 166 | 10 | M8239 |
| Coexpression | MANNO_MIDBRAIN_NEUROTYPES_HNBML5 | PAK5 ANKS1B PITPNC1 GRIP1 AATK NALF1 TOX3 SERTAD4 ZFHX2 ZFHX3 HERC1 BSN SAMD14 TOX2 NOVA1 | 3.00e-07 | 465 | 166 | 15 | M39066 |
| Coexpression | LINDGREN_BLADDER_CANCER_CLUSTER_2B | TCF4 HHEX TOX SREBF1 NR4A1 SLC2A4RG EGR1 MICAL2 SDC3 MAFB TNFAIP3 NEURL1B MAF | 1.29e-06 | 389 | 166 | 13 | M4995 |
| Coexpression | LAKE_ADULT_KIDNEY_C17_COLLECTING_SYSTEM_PCS_STRESSED_DISSOC_SUBSET | 3.28e-06 | 240 | 166 | 10 | M39236 | |
| Coexpression | GSE22229_RENAL_TRANSPLANT_VS_HEALTHY_PBMC_DN | 5.09e-06 | 198 | 166 | 9 | M7480 | |
| Coexpression | GSE21379_WT_VS_SAP_KO_TFH_CD4_TCELL_DN | 5.30e-06 | 199 | 166 | 9 | M7498 | |
| Coexpression | AMIT_EGF_RESPONSE_40_HELA | 6.75e-06 | 42 | 166 | 5 | M4204 | |
| Coexpression | HARALAMBIEVA_PBMC_FLUARIX_AGE_50_74YO_CORR_WITH_28D_MEM_B_CELL_RESPONSE_AT_28DY_POSITIVE | TET2 TCF4 OXER1 CEBPB CEACAM4 LRRK1 NR4A1 MED13L ZFP36 PXK KSR1 ARHGEF40 MIDN MCTP1 AP2A1 MICAL2 KCTD3 TIGD3 MAFB ZFHX3 ELL GAB1 | 1.42e-05 | 1250 | 166 | 22 | M41099 |
| Coexpression | HARALAMBIEVA_PBMC_FLUARIX_AGE_50_74YO_CORR_WITH_28D_MEM_B_CELL_RESPONSE_AT_3DY_POSITIVE | CEBPB LRRK1 MED13L ZFP36 PXK KSR1 MIDN EGR1 MICAL2 KCTD3 TNFAIP3 | 2.44e-05 | 368 | 166 | 11 | M41100 |
| Coexpression | GSE8515_IL1_VS_IL6_4H_STIM_MAC_DN | 3.47e-05 | 194 | 166 | 8 | M5767 | |
| Coexpression | TABULA_MURIS_SENIS_BRAIN_NON_MYELOID_NEURON_AGEING | PCGF2 SREBF2 ADGRL1 TNIP1 MED13L STK11IP ZFP36 USP31 ARHGEF40 AP2A1 MEGF8 DOCK7 ZFHX2 BSN ELL MAST3 NOVA1 INO80E | 3.73e-05 | 954 | 166 | 18 | MM3689 |
| Coexpression | GSE2770_IL12_VS_TGFB_AND_IL12_TREATED_ACT_CD4_TCELL_6H_UP | 3.87e-05 | 197 | 166 | 8 | M6059 | |
| Coexpression | GSE45365_NK_CELL_VS_CD8_TCELL_MCMV_INFECTION_DN | 4.30e-05 | 200 | 166 | 8 | M9961 | |
| Coexpression | GSE1925_3H_VS_24H_IFNG_STIM_IFNG_PRIMED_MACROPHAGE_DN | 4.30e-05 | 200 | 166 | 8 | M6301 | |
| Coexpression | MURARO_PANCREAS_PANCREATIC_POLYPEPTIDE_CELL | 5.62e-05 | 153 | 166 | 7 | M39171 | |
| Coexpression | NABA_ECM_AFFILIATED | 6.89e-05 | 158 | 166 | 7 | MM17063 | |
| Coexpression | GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_DN | TET2 TCF4 ATXN7L2 RTN4 MAFA SRCAP STK11IP WAC AATK FBXO10 PRRC2C DOCK7 ZFHX3 CORO7 CABIN1 PDLIM2 GAB1 PARM1 MAF | 7.51e-05 | 1102 | 166 | 19 | M2369 |
| Coexpression | GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_DN | TET2 TCF4 ATXN7L2 RTN4 MAFA SRCAP STK11IP WAC AATK FBXO10 PRRC2C DOCK7 ZFHX3 CORO7 CABIN1 PDLIM2 GAB1 PARM1 MAF | 9.73e-05 | 1124 | 166 | 19 | MM1070 |
| Coexpression | KOYAMA_SEMA3B_TARGETS_DN | 1.15e-04 | 364 | 166 | 10 | M2029 | |
| Coexpression | GSE14415_ACT_TCONV_VS_ACT_NATURAL_TREG_UP | 1.17e-04 | 172 | 166 | 7 | M2945 | |
| Coexpression | DAZARD_RESPONSE_TO_UV_NHEK_DN | 1.32e-04 | 300 | 166 | 9 | M8702 | |
| Coexpression | GSE4590_LARGE_PRE_BCELL_VS_VPREB_POS_LARGE_PRE_BCELL_DN | 1.55e-04 | 180 | 166 | 7 | M6878 | |
| Coexpression | MANNO_MIDBRAIN_NEUROTYPES_HNBGABA | PAK5 FNBP1L PXK AATK NALF1 PDE4DIP SERTAD4 TIGD3 ZFHX2 SDC3 ZFHX3 BSN TOX2 NPAS4 | 1.63e-04 | 703 | 166 | 14 | M39070 |
| Coexpression | BROWNE_HCMV_INFECTION_18HR_DN | 1.66e-04 | 182 | 166 | 7 | M6641 | |
| Coexpression | BUSSLINGER_GASTRIC_IMMUNE_CELLS | TOX ZBTB4 ICE1 NR3C1 PITPNC1 ZFP36 PRDM2 WAC CCDC88C HEG1 SLC2A4RG LAT SBNO1 PDE4DIP KMT2A TNFAIP3 HERC1 USP1 PDLIM2 ELL MAST3 MAF | 1.93e-04 | 1492 | 166 | 22 | M40023 |
| Coexpression | WEST_ADRENOCORTICAL_TUMOR_DN | PCGF2 PATZ1 PAK5 SREBF1 NR4A1 ZFP36 TOB1 EGR1 MICAL2 MEPCE KMT2A MUC2 | 1.98e-04 | 546 | 166 | 12 | M3837 |
| Coexpression | RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN | TCF4 HHEX NELFA ZBTB4 MED13L IRAG1 MAP3K1 RSBN1 KSR1 TOB1 ZFHX3 TNFAIP3 HERC1 CABIN1 MAF | 2.00e-04 | 807 | 166 | 15 | M16651 |
| Coexpression | HOEK_NK_CELL_2011_2012_TIV_3D_VS_0DY_ADULT_3D_DN | 2.50e-04 | 258 | 166 | 8 | M41144 | |
| Coexpression | GSE21670_UNTREATED_VS_IL6_TREATED_CD4_TCELL_UP | 2.78e-04 | 198 | 166 | 7 | M7459 | |
| Coexpression | GSE24671_CTRL_VS_SENDAI_VIRUS_INFECTED_MOUSE_SPLENOCYTES_DN | 2.87e-04 | 199 | 166 | 7 | M9443 | |
| Coexpression | GSE22886_NAIVE_CD4_TCELL_VS_12H_ACT_TH1_UP | 2.87e-04 | 199 | 166 | 7 | M4521 | |
| Coexpression | GSE2770_IL12_VS_IL4_TREATED_ACT_CD4_TCELL_48H_DN | 2.87e-04 | 199 | 166 | 7 | M6030 | |
| Coexpression | GSE360_CTRL_VS_T_GONDII_DC_UP | 2.87e-04 | 199 | 166 | 7 | M5147 | |
| Coexpression | GSE22589_HEALTHY_VS_SIV_INFECTED_DC_UP | 2.87e-04 | 199 | 166 | 7 | M7798 | |
| Coexpression | GSE10239_NAIVE_VS_KLRG1INT_EFF_CD8_TCELL_UP | 2.87e-04 | 199 | 166 | 7 | M3050 | |
| Coexpression | GSE27786_LIN_NEG_VS_CD4_TCELL_DN | 2.96e-04 | 200 | 166 | 7 | M4773 | |
| Coexpression | GSE9960_GRAM_POS_VS_GRAM_NEG_AND_POS_SEPSIS_PBMC_UP | 2.96e-04 | 200 | 166 | 7 | M7132 | |
| Coexpression | GSE21379_TFH_VS_NON_TFH_CD4_TCELL_UP | 2.96e-04 | 200 | 166 | 7 | M7500 | |
| Coexpression | GSE32423_MEMORY_VS_NAIVE_CD8_TCELL_DN | 2.96e-04 | 200 | 166 | 7 | M5073 | |
| Coexpression | GSE5542_UNTREATED_VS_IFNA_TREATED_EPITHELIAL_CELLS_24H_UP | 2.96e-04 | 200 | 166 | 7 | M6524 | |
| Coexpression | GSE3982_BCELL_VS_BASOPHIL_DN | 2.96e-04 | 200 | 166 | 7 | M5540 | |
| Coexpression | IVANOVA_HEMATOPOIESIS_STEM_CELL_AND_PROGENITOR | ABL1 CEACAM4 FNBP1L FOXB1 KRBA1 MIDN NALF1 MICAL2 PRRC2C BSN PARM1 INO80E | 3.11e-04 | 574 | 166 | 12 | M8215 |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L3-5_SST_MAFB|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | KIF26B PITPNC1 GRIP1 HEG1 ARHGEF40 AMOTL1 TOX3 MAFB TOX2 NPAS1 MAF | 1.90e-10 | 194 | 166 | 11 | 83863da11dfbe59b2d0a2c08db40b537c150588c |
| ToppCell | Neuronal-Inhibitory-iB-iB_4(SST)|Neuronal / cells hierarchy compared to all cells using T-Statistic | KIF26B PITPNC1 GRIP1 HEG1 ARHGEF40 AMOTL1 TOX3 MAFB TOX2 NPAS1 MAF | 2.63e-10 | 200 | 166 | 11 | 347a510755374c6a66acee326565dfc447993f18 |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.60e-09 | 196 | 166 | 10 | 7af6c5147ac859353504d19727dbe24f63a29dd4 | |
| ToppCell | Neuronal-Inhibitory-iB-iB_4(SST)-ADGRG6-|Neuronal / cells hierarchy compared to all cells using T-Statistic | KIF26B PITPNC1 GRIP1 HEG1 ARHGEF40 AMOTL1 TOX3 MAFB TOX2 MAF | 4.38e-09 | 200 | 166 | 10 | a9cdddc4e985dae59521e557479c24fcc2ac727d |
| ToppCell | mild-HLA-DR+_CD83+_Monocyte|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 4.38e-09 | 200 | 166 | 10 | 934c2efc780318c66d667ca75be0de350361d351 | |
| ToppCell | Neuronal-Inhibitory-iB-iB_4(SST)-ADGRG6|Neuronal / cells hierarchy compared to all cells using T-Statistic | KIF26B PITPNC1 GRIP1 HEG1 ARHGEF40 AMOTL1 TOX3 MAFB TOX2 MAF | 4.38e-09 | 200 | 166 | 10 | 9719fabddc34051949468a7520289e3c750de4f8 |
| ToppCell | Neuronal-Inhibitory-iB-iB_4(SST)-ADGRG6--L3-5|Neuronal / cells hierarchy compared to all cells using T-Statistic | KIF26B PITPNC1 GRIP1 HEG1 ARHGEF40 AMOTL1 TOX3 MAFB TOX2 MAF | 4.38e-09 | 200 | 166 | 10 | 33b9199e0dfc267e2cea20b82d1c167f8adcc635 |
| ToppCell | primary_visual_cortex-Neuronal-GABAergic_neuron-Sst-Sst_Chrna2_Glra3|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 9.53e-09 | 160 | 166 | 9 | 0bfdaf979e6f128cba2928ce16bca4d3deff8ac9 | |
| ToppCell | Smart-seq2-blood_(Smart-seq2)-myeloid-myeloid_monocytic-classical_monocyte|blood_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 3.52e-08 | 186 | 166 | 9 | 23b8d51d20b05795a73892d3e20e0f9b6a207820 | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 4.83e-08 | 193 | 166 | 9 | d1445b8bf2bab36e1a326ddb2a528151db016c7d | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 4.83e-08 | 193 | 166 | 9 | 2189da4b727e25e62669d7b9257f06493be21a27 | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 4.83e-08 | 193 | 166 | 9 | 3ed46f5a7419ec4eddbd0df0d9b5f53aa486198b | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L3-5_SST_MAFB|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 4.83e-08 | 193 | 166 | 9 | e74fdc8718fe0933e1f4dd3fe37e2134983b99b6 | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L3-5_SST_MAFB|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 4.83e-08 | 193 | 166 | 9 | 658c2b30a4d806c5ce78ea4392fe8eb86b8d1e99 | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 5.05e-08 | 194 | 166 | 9 | 02a9cc821c2b14aa7d0e55661a5fab66364474e1 | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 5.05e-08 | 194 | 166 | 9 | 4f758718a1233c25c25d99fc1b7b06f906b8b0a2 | |
| ToppCell | Caecum-T_cell-Treg|T_cell / Region, Cell class and subclass | 6.02e-08 | 198 | 166 | 9 | 90a2a75ca078f7088b8739795a9b396113bcbe23 | |
| ToppCell | Neuronal-Inhibitory-iB-iB_4(SST)-STK32A--L4-5|Neuronal / cells hierarchy compared to all cells using T-Statistic | 6.56e-08 | 200 | 166 | 9 | cb1f4b0d66da5b0466ff17b29e7034d451d93e4f | |
| ToppCell | Neuronal-Inhibitory|Neuronal / cells hierarchy compared to all cells using T-Statistic | 6.56e-08 | 200 | 166 | 9 | 9ff8647e2de0b538e15929dca88ebb20ff7ab043 | |
| ToppCell | Neuronal-Inhibitory-iB-iB_4(SST)-STK32A-|Neuronal / cells hierarchy compared to all cells using T-Statistic | 6.56e-08 | 200 | 166 | 9 | 6a44439e4a7ce3627271375b04cfcfb9467218f4 | |
| ToppCell | Neuronal-Inhibitory-iB-iB_4(SST)-STK32A|Neuronal / cells hierarchy compared to all cells using T-Statistic | 6.56e-08 | 200 | 166 | 9 | 8d51b4f7b7002ee51401ebe5eaca1e8f04bfadd5 | |
| ToppCell | primary_visual_cortex-Neuronal-GABAergic_neuron-Sst-Sst_Hpse_Sema3c|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 1.26e-07 | 155 | 166 | 8 | 5c7b68b59244525e3714806c205a57a2daebf423 | |
| ToppCell | primary_visual_cortex-Neuronal-GABAergic_neuron-Sst-Sst_Calb2_Pdlim5|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 1.61e-07 | 160 | 166 | 8 | dd16ca90feb3ae88b6409d6c278b4765da565514 | |
| ToppCell | 356C-Myeloid-Monocyte-CD16+_Monocyte|356C / Donor, Lineage, Cell class and subclass (all cells) | 2.03e-07 | 165 | 166 | 8 | 35a6de30438de364ccca948fc932da541a69ef89 | |
| ToppCell | Primary_Visual_cortex_(V1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L3-5_SST_MAFB|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 5.07e-07 | 186 | 166 | 8 | 96f6603cc75fa1ffc2a2fdb94ec0ec09498e540a | |
| ToppCell | facs-Mammary_Gland-Mammary_Gland-18m|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.49e-07 | 188 | 166 | 8 | 5e13725136114e42d3b59647cf25e0f3c53abb54 | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 5.95e-07 | 190 | 166 | 8 | 56cc761e50fddfb5366391518b4d8e16589b6b42 | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L2-4_PVALB_C8orf4|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 5.95e-07 | 190 | 166 | 8 | e58e4b6fbeb4368f738adac67ec10879c0966f0f | |
| ToppCell | Brain_organoid-organoid_Paulsen_bioRxiv-3.5_mon-Neuronal-Immature_INs|3.5_mon / Sample Type, Dataset, Time_group, and Cell type. | 5.95e-07 | 190 | 166 | 8 | 842760bfe0a52e67bad800efa7d99448a4a23ebb | |
| ToppCell | facs-Mammary_Gland-Mammary_Gland-18m-Epithelial|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.95e-07 | 190 | 166 | 8 | 92456f6f7eced6e4c4371f495254a65d061c8d0b | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_1|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 5.95e-07 | 190 | 166 | 8 | 25d4b591f75c26e404a34c42f1742d580af6598d | |
| ToppCell | COVID-19-Heart-EC_+_Pericyte|Heart / Disease (COVID-19 only), tissue and cell type | 5.95e-07 | 190 | 166 | 8 | a21653bfb7bafbc273f94fa7c13bfb48cf8fd562 | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L2-4_SST_AHR|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 6.19e-07 | 191 | 166 | 8 | 782bc7946417549ffd39e5b596db659436fa01ba | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 6.44e-07 | 192 | 166 | 8 | bf1943715085c4124b1675888b0615c9500ec888 | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5-Inh_L1-4_LAMP5_DUSP4_(Lamp5_Rosehip)|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 6.44e-07 | 192 | 166 | 8 | 342842378c20267c5044bdd622515e8b9f895623 | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_3|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 6.70e-07 | 193 | 166 | 8 | 4979862c0c16e6b4baa4c79894f1d237c861f5a5 | |
| ToppCell | Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 6.70e-07 | 193 | 166 | 8 | 9f9eb241b0b82a6f12de6921c3acf6fed7cf65bb | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L3-5_SST_MAFB|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 6.97e-07 | 194 | 166 | 8 | 1bcb3fafd498614f7bac2b1c9b7de56e39110f65 | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_3|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 6.97e-07 | 194 | 166 | 8 | e5990880961d2469759ce4b3b20ae93ace3ebd1f | |
| ToppCell | 10x3'2.3-week_17-19|World / cell types per 3 fetal stages;per 3',per 5' | 7.82e-07 | 197 | 166 | 8 | f5cfad0b42d0f817e22cc78b9bfb2b4b7e4330ed | |
| ToppCell | Caecum-T_cell-Th1|T_cell / Region, Cell class and subclass | 8.44e-07 | 199 | 166 | 8 | 13a80e6d3cf9c831edbe0644545071153e35f82b | |
| ToppCell | Neuronal-Inhibitory-iB-iB_4(SST)-B3GAT2|Neuronal / cells hierarchy compared to all cells using T-Statistic | 8.76e-07 | 200 | 166 | 8 | 858421b91f5207b7934b5c219752cb9322a3da31 | |
| ToppCell | Brain_organoid-organoid_Tanaka_cellReport-5w-Neuronal-Intermediate|5w / Sample Type, Dataset, Time_group, and Cell type. | 8.76e-07 | 200 | 166 | 8 | c92e4fc0442404481fcac623d691dae6215b852d | |
| ToppCell | Neuronal-Inhibitory-iB-iB_4(SST)-B3GAT2-|Neuronal / cells hierarchy compared to all cells using T-Statistic | 8.76e-07 | 200 | 166 | 8 | a7022762c1d8aedb7b3e9605873b1e68b9907b35 | |
| ToppCell | Neuronal-Inhibitory-iB-iB_3(PVALB-SST)-FRZB--L2-4|Neuronal / cells hierarchy compared to all cells using T-Statistic | 8.76e-07 | 200 | 166 | 8 | 5ec469267747dce3601c1d8ad01af89fa5b29acc | |
| ToppCell | Neuronal-Inhibitory-iB-iB_2(PVALB)-WFDC2--L2-4|Neuronal / cells hierarchy compared to all cells using T-Statistic | 8.76e-07 | 200 | 166 | 8 | c65e6336725856c4b5f6aeba1cf86a23ec815d34 | |
| ToppCell | Neuronal-Inhibitory-iB-iB_3(PVALB-SST)-FRZB|Neuronal / cells hierarchy compared to all cells using T-Statistic | 8.76e-07 | 200 | 166 | 8 | e79d93d55b25804f2608185168da472301b6ebca | |
| ToppCell | Neuronal-Inhibitory-iB-iB_2(PVALB)-WFDC2-|Neuronal / cells hierarchy compared to all cells using T-Statistic | 8.76e-07 | 200 | 166 | 8 | 117a25b3b9cdbc2e198381350a8362bee25e82e7 | |
| ToppCell | Neuronal-Inhibitory-iB-iB_4(SST)-B3GAT2--L4-6|Neuronal / cells hierarchy compared to all cells using T-Statistic | 8.76e-07 | 200 | 166 | 8 | 2131c8e7fa054b79906eaf60536da892438b09cd | |
| ToppCell | Neuronal-Inhibitory-iB|Neuronal / cells hierarchy compared to all cells using T-Statistic | 8.76e-07 | 200 | 166 | 8 | 45ddc5ef2caa87ada88327b63ba9b150a6bb3aa5 | |
| ToppCell | Neuronal-Inhibitory-iB-iB_2(PVALB)-WFDC2|Neuronal / cells hierarchy compared to all cells using T-Statistic | 8.76e-07 | 200 | 166 | 8 | d459e51507bf26865e6e7e04411379ec82a3edf8 | |
| ToppCell | Neuronal-Inhibitory-iB-iB_3(PVALB-SST)-FRZB-|Neuronal / cells hierarchy compared to all cells using T-Statistic | 8.76e-07 | 200 | 166 | 8 | 320d5a3a1e7da2fa8f1a164e29e180ec8ac9889c | |
| ToppCell | primary_visual_cortex-Neuronal-GABAergic_neuron-Sst-Sst_Chrna2_Ptgdr|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 1.18e-06 | 144 | 166 | 7 | 71107275767a0728541a3695715c44874b3e5efc | |
| ToppCell | normal_Lymph_Node-Myeloid_cells-mo-Mac|Myeloid_cells / Location, Cell class and cell subclass | 1.77e-06 | 153 | 166 | 7 | 5424494ea1f09542799045a875cc3eac13de5079 | |
| ToppCell | Frontal_cortex-Neuronal-Inhibitory|Frontal_cortex / BrainAtlas - Mouse McCarroll V32 | 3.42e-06 | 169 | 166 | 7 | 78eb70dd916724e476eabccf18fb7fcec4210308 | |
| ToppCell | primary_visual_cortex-Neuronal-GABAergic_neuron-Sst|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 3.56e-06 | 170 | 166 | 7 | 8ab67e2b6e30fdf9e9a2c02e31d4df34e751a3ed | |
| ToppCell | frontal_cortex-Neuronal-GABAergic_neuron-Vip|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 3.70e-06 | 171 | 166 | 7 | 5efd15300f865ebf651e0888265cbd717bc3b9d3 | |
| ToppCell | 5'-Adult-LargeIntestine-Epithelial-goblet-Goblet_cell|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 3.70e-06 | 171 | 166 | 7 | 48125d825ca2d7ef34564250f5b47d2a579e03c9 | |
| ToppCell | 3'-GW_trimst-1.5-SmallIntestine-Neuronal-Glial_immature-ENCC/glia_Progenitor|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 3.99e-06 | 173 | 166 | 7 | 23e50492bc673aff9df95d97f0b9be4ce57cbf01 | |
| ToppCell | wk_20-22-Hematologic_Lymphocytic-T_&_ILC-ILCP|wk_20-22 / Celltypes from embryonic and fetal-stage human lung | 4.15e-06 | 174 | 166 | 7 | 5e6050d20a5b27640f6a200441125b8ceba123c8 | |
| ToppCell | 356C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_6|CD8+_Cytotoxic_T-cell / Donor, Lineage, Cell class and subclass (all cells) | 4.31e-06 | 175 | 166 | 7 | f3a68aeb79c4935006e17a5ff3445a8ec0e33f5f | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L2-4_SST_AHR|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 4.47e-06 | 176 | 166 | 7 | 322259a35f5c97d73ce7f75835dcdb5c954c91f8 | |
| ToppCell | normal_Lymph_Node-T/NK_cells-Exhausted_CD8+_T|normal_Lymph_Node / Location, Cell class and cell subclass | 5.00e-06 | 179 | 166 | 7 | 3dc929a10381b7d86650c6cd8f354892fe1d93e7 | |
| ToppCell | renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Collecting_tubule_epithelial_cell-kidney_connecting_tubule_epithelial_cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 5.18e-06 | 180 | 166 | 7 | 788d5fbf688365b5d92d3aa19b9f8e9448f8be5a | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L3-4_PVALB_HOMER3|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 5.37e-06 | 181 | 166 | 7 | bd7e9437839bca543ca5945df43d6525e6a312a8 | |
| ToppCell | frontal_cortex-Neuronal-GABAergic_neuron|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 5.57e-06 | 182 | 166 | 7 | f2a1784ffcba9b27132e0db21e574cbd8a0a6418 | |
| ToppCell | renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Collecting_tubule_epithelial_cell-kidney_connecting_tubule_epithelial_cell-Connecting_Tubule_Principal_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 5.57e-06 | 182 | 166 | 7 | f96095b81188b52db8fcfca4837129cfcd9bd7b7 | |
| ToppCell | COVID-19-Heart-Fib_+_EC_+_Pericyte|COVID-19 / Disease (COVID-19 only), tissue and cell type | 5.57e-06 | 182 | 166 | 7 | fbd5e332df73bf7141c822fa67b76367dc962017 | |
| ToppCell | Smart-seq2-lymph_node_(Smart-seq2)-lymphocytic-innate_lymphocytic-innate_lymphoid_cell|lymph_node_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 5.57e-06 | 182 | 166 | 7 | b86690c109cdc16844a6cd2216c1bf2bf28efd45 | |
| ToppCell | LV-07._Pericyte|World / Chamber and Cluster_Paper | 5.78e-06 | 183 | 166 | 7 | 273db6a3b00a93ca852498471187b642b5368185 | |
| ToppCell | COVID-19-Heart-EC_3|COVID-19 / Disease (COVID-19 only), tissue and cell type | 5.78e-06 | 183 | 166 | 7 | ff95382cfed592190d0636d2b750328471f82e0d | |
| ToppCell | Primary_Visual_cortex_(V1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L4-5_PVALB_TRIM67|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 5.99e-06 | 184 | 166 | 7 | 7f6c8912677764d438ab0555faca344d74c2f483 | |
| ToppCell | COVID-19-Heart-Pericyte|Heart / Disease (COVID-19 only), tissue and cell type | 5.99e-06 | 184 | 166 | 7 | 21790cdfa3b4036ad413fd44b94e31563116f25f | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_convalescent_d42-56-Myeloid-Granulocytic-Neutrophil-Neu_c1-IL1B|Severe-critical_convalescent_d42-56 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 6.42e-06 | 186 | 166 | 7 | 05c40bac5c0ade8b67b7c2112739466e02dbf22b | |
| ToppCell | Smart-seq2-lymph_node_(Smart-seq2)-lymphocytic-innate_lymphocytic|lymph_node_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 6.42e-06 | 186 | 166 | 7 | 855c2e5a8a6cf94c7de31982e0e2416f924439d3 | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5-Inh_L1_LAMP5_NDNF|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 6.42e-06 | 186 | 166 | 7 | 310d16f4e5cffee3ea6d7635508c513a3b92131e | |
| ToppCell | Primary_Visual_cortex_(V1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 6.65e-06 | 187 | 166 | 7 | 85f1678338a47d91e296f0620d4887f057eb7e70 | |
| ToppCell | renal_cortex_nuclei-Adult_normal_reference-Endothelial-blood_vessel_endothelial_cell_of_kidney-capillary-immature_endothelial_cell-Peritubular_Capilary_Endothelial_Cell__prolif|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 6.65e-06 | 187 | 166 | 7 | 35c382c0aabd46906113e5db30ea24bb8e658899 | |
| ToppCell | LPS-antiTNF-Endothelial-Endothelial-Alv_Gen_Intermediate|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.89e-06 | 188 | 166 | 7 | 789d1be574e693d7bdd488f3c72c6df788e47b47 | |
| ToppCell | 3'_v3-Lung-Lymphocytic_T_CD4-Trm_Th1/Th17|Lung / Manually curated celltypes from each tissue | 7.13e-06 | 189 | 166 | 7 | f43960506ed3e699e910ec7711c1113e2e9b80d1 | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L4-6_SST_MTHFD2P6|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 7.13e-06 | 189 | 166 | 7 | 06c44746fa4f02e6e2b3b635cdf2d8dfef3754d3 | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5-Inh_L1_LAMP5_NDNF|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 7.13e-06 | 189 | 166 | 7 | f0aaf2994d319a39877d2845eaab9f166adead4e | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5-Inh_L1-4_LAMP5_DUSP4_(Lamp5_Rosehip)|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 7.13e-06 | 189 | 166 | 7 | 979b7fa947538aa7ca4a219263da2575869a2caa | |
| ToppCell | E17.5-Endothelial-large_vessel_endothelial_cell|E17.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 7.13e-06 | 189 | 166 | 7 | 360f09f46231a83f99d8fa0158b72a38068e1642 | |
| ToppCell | Primary_Visual_cortex_(V1C)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 7.38e-06 | 190 | 166 | 7 | 3b8d1e66ae68c1eee64095e75195d76d97e24026 | |
| ToppCell | (0)_Normal/No_Treatment-(1)_VE-Cad+_vascular_cells|World / Stress and Cell class | 7.38e-06 | 190 | 166 | 7 | ff083168d609957d00888f31b3488d6d56c902b4 | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 7.38e-06 | 190 | 166 | 7 | 305fbef734c350cfbf786ca7ff6e07093aab56ea | |
| ToppCell | Primary_Visual_cortex_(V1C)-Neuronal-Inh_GABAergic-i_Gaba_1|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 7.38e-06 | 190 | 166 | 7 | dc655e4782aab274f0c9b6e36a5ce315e3a1a4b9 | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L2-4_PVALB_C8orf4|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 7.38e-06 | 190 | 166 | 7 | 0acf1d5da68db449d8c9e70519a236ce825f9d11 | |
| ToppCell | renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast-Adaptive_/_Maladaptive_/_Repairing_Fibroblast|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 7.64e-06 | 191 | 166 | 7 | 2c51850f5c559d665b8a27a12b75af9ed58dffe1 | |
| ToppCell | primary_visual_cortex-Neuronal-GABAergic_neuron-Sst-Sst_Hpse_Cbln4|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 7.87e-06 | 126 | 166 | 6 | 94bd9cfe982b41a3114885173eab55feb0fbbbae | |
| ToppCell | facs-Mammary_Gland-Mammary_Gland-18m-Epithelial-basal_cell|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.90e-06 | 192 | 166 | 7 | c47df468cf78a90929913c9022e8078a53cdf680 | |
| ToppCell | 3'_v3-lymph-node_spleen-Lymphocytic_T_CD4-Tregs|lymph-node_spleen / Manually curated celltypes from each tissue | 7.90e-06 | 192 | 166 | 7 | 91a4d06e8d1d1fe2ce5f72668108513bd2a72c4d | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 7.90e-06 | 192 | 166 | 7 | f6ec683b2133b3095a1fcc06ca8605cf38f774b5 | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5-Inh_L1-4_LAMP5_DUSP4_(Lamp5_Rosehip)|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 7.90e-06 | 192 | 166 | 7 | bd3fa6c8fcb618db64d11f25cabaf08608957c35 | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_1|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 7.90e-06 | 192 | 166 | 7 | 690b3d17c481159bc96b8bc7f6a66b51343ee858 | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 8.18e-06 | 193 | 166 | 7 | 010717ca052b6c8a525a43aaeffddea0d1113e63 | |
| ToppCell | Neuron-Postmitotic-Inhibitory_Neuron-SST-MGE1-4|World / Primary Cells by Cluster | 8.18e-06 | 193 | 166 | 7 | 2eb6e4cff4fe3ce564c1581f6f7df4834895aaa9 | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_3|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 8.18e-06 | 193 | 166 | 7 | 53bcd50892c379b2a571751f6eb1062436339fe7 | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L4-6_SST_MTHFD2P6|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 8.18e-06 | 193 | 166 | 7 | 8b77625bf3c87d39767fb391d1beaca4ab02342b | |
| Drug | Calycanthine [595-05-1]; Down 200; 11.6uM; PC3; HT_HG-U133A | CEACAM4 SREBF2 ADGRL1 NR4A1 SRCAP PPP4R4 EVI5 CCDC88C BAZ2A SUGP1 PLCB3 CABIN1 | 2.14e-08 | 195 | 166 | 12 | 5744_DN |
| Drug | (1-[(4-Chlorophenyl)phenyl-methyl]-4-methylpiperazine) [1620-21-9]; Up 200; 11.8uM; MCF7; HT_HG-U133A | NRL SOX30 EGR1 MICAL2 SCN5A SUGP1 AGFG2 ZFHX2 KMT2A TNFAIP3 MAF | 2.14e-07 | 196 | 166 | 11 | 6053_UP |
| Drug | Carbinoxamine maleate salt [3505-38-2]; Up 200; 9.8uM; PC3; HT_HG-U133A | PCGF2 ADGRL1 EGR1 MICAL2 SUGP1 ZFHX3 TNFAIP3 PDLIM2 MUC7 MAST3 MAF | 2.26e-07 | 197 | 166 | 11 | 7138_UP |
| Drug | Remoxipride Hydrochloride [73220-03-8]; Down 200; 9.8uM; HL60; HT_HG-U133A | 1.60e-06 | 193 | 166 | 10 | 3124_DN | |
| Drug | Succimer | TET2 TCF4 PCGF2 TRPM7 PATZ1 RTN4 DTL ZBTB4 TNIP1 NR3C1 ZFP36 PXK PRDM2 EVI5 EGR1 MICAL2 STARD9 PDE4DIP AGFG2 JAZF1 SDC3 MAFB TNFAIP3 USP1 TOX2 KAT14 | 1.61e-06 | 1264 | 166 | 26 | ctd:D004113 |
| Drug | Cyclobenzaprine hydrochloride [6202-23-9]; Up 200; 12.8uM; PC3; HT_HG-U133A | NRL CEACAM4 SRCAP KSR1 HEG1 BAZ2A MICAL2 PDE4DIP SUGP1 TNFAIP3 | 1.84e-06 | 196 | 166 | 10 | 4252_UP |
| Drug | Imipenem [74431-23-5]; Up 200; 13.4uM; MCF7; HT_HG-U133A | CEACAM4 NR3C1 SRCAP EVI5 ARHGEF40 SNCAIP LAT EGR1 BAZ2A TNFAIP3 | 1.93e-06 | 197 | 166 | 10 | 2873_UP |
| Drug | Verapamyl hydrochloride [152-11-4]; Down 200; 8.2uM; PC3; HT_HG-U133A | TOX UBE4B ARHGAP10 PATZ1 ADGRL1 STAC PDE4DIP SDC3 PDLIM2 MUC7 | 2.02e-06 | 198 | 166 | 10 | 6287_DN |
| Drug | Amethopterin (R,S) [59-05-2]; Up 200; 8.8uM; PC3; HT_HG-U133A | 2.11e-06 | 199 | 166 | 10 | 6654_UP | |
| Drug | Magnetite Nanoparticles | TET2 TCF4 PCGF2 TRPM7 PATZ1 RTN4 DTL ZBTB4 TNIP1 NR3C1 ZFP36 PXK PRDM2 EVI5 EGR1 MICAL2 STARD9 PDE4DIP AGFG2 JAZF1 SDC3 MAFB TNFAIP3 USP1 TOX2 KAT14 | 3.09e-06 | 1310 | 166 | 26 | ctd:D058185 |
| Drug | rioprostil | 3.33e-06 | 32 | 166 | 5 | CID005311413 | |
| Drug | cellobiitol | 7.00e-06 | 37 | 166 | 5 | CID000003871 | |
| Drug | trichostatin A, Streptomyces sp.; Up 200; 1uM; PC3; HT_HG-U133A | 7.21e-06 | 180 | 166 | 9 | 5950_UP | |
| Drug | Miconazole [22916-47-8]; Up 200; 9.6uM; MCF7; HT_HG-U133A | 7.21e-06 | 180 | 166 | 9 | 1477_UP | |
| Drug | Ticlopidine hydrochloride [53885-35-1]; Up 200; 13.4uM; MCF7; HT_HG-U133A | 8.24e-06 | 183 | 166 | 9 | 1475_UP | |
| Drug | Perphenazine [58-39-9]; Up 200; 10uM; MCF7; HT_HG-U133A | 8.61e-06 | 184 | 166 | 9 | 1540_UP | |
| Drug | p-Chloromercuribenzoic Acid | TET2 CEBPB SREBF2 RFX4 ZFP36 PXK MSX2 RSBN1 HEG1 ARHGEF40 SNCAIP NALF1 MCTP1 EGR1 ZFR2 DOCK7 JAZF1 KMT2A KAT14 MAF | 1.08e-05 | 908 | 166 | 20 | ctd:D020245 |
| Drug | Etofenamate [30544-47-9]; Up 200; 10.8uM; MCF7; HT_HG-U133A | 1.21e-05 | 192 | 166 | 9 | 4108_UP | |
| Drug | radicicol; Down 200; 0.1uM; PC3; HT_HG-U133A | 1.32e-05 | 194 | 166 | 9 | 5952_DN | |
| Drug | Harmaline hydrochloride dihydrate [6027-98-1]; Up 200; 14uM; MCF7; HT_HG-U133A | 1.37e-05 | 195 | 166 | 9 | 2805_UP | |
| Drug | Cinoxacin [28657-80-9]; Down 200; 15.2uM; PC3; HT_HG-U133A | 1.37e-05 | 195 | 166 | 9 | 5783_DN | |
| Drug | Ursolic acid [77-52-1]; Down 200; 8.8uM; MCF7; HT_HG-U133A | 1.43e-05 | 196 | 166 | 9 | 7181_DN | |
| Drug | Dipyridamole [58-32-2]; Down 200; 8uM; PC3; HT_HG-U133A | 1.43e-05 | 196 | 166 | 9 | 4656_DN | |
| Drug | AG-012559 [369370-06-9]; Down 200; 10uM; PC3; HT_HG-U133A | 1.43e-05 | 196 | 166 | 9 | 6884_DN | |
| Drug | Lysergol [602-85-7]; Up 200; 15.8uM; MCF7; HT_HG-U133A | 1.43e-05 | 196 | 166 | 9 | 3261_UP | |
| Drug | 2-propylpentanoic acid; Up 200; 200uM; PC3; HT_HG-U133A | 1.49e-05 | 197 | 166 | 9 | 4438_UP | |
| Drug | Propidium iodide [25535-16-4]; Down 200; 6uM; PC3; HT_HG-U133A | 1.49e-05 | 197 | 166 | 9 | 5803_DN | |
| Drug | Sulindac [38194-50-2]; Up 200; 11.2uM; MCF7; HT_HG-U133A | 1.49e-05 | 197 | 166 | 9 | 1693_UP | |
| Drug | Memantine Hydrochloride [41100-52-1]; Up 200; 18.6uM; MCF7; HT_HG-U133A | 1.49e-05 | 197 | 166 | 9 | 4135_UP | |
| Drug | Epitiostanol [2363-58-8]; Down 200; 13uM; MCF7; HT_HG-U133A | 1.55e-05 | 198 | 166 | 9 | 4788_DN | |
| Drug | Meclofenamic acid sodium salt monohydrate [6385-02-0]; Up 200; 11.8uM; PC3; HT_HG-U133A | 1.55e-05 | 198 | 166 | 9 | 2128_UP | |
| Drug | Idazoxan hydrochloride [79944-56-2]; Down 200; 16.6uM; MCF7; HT_HG-U133A | 1.61e-05 | 199 | 166 | 9 | 6465_DN | |
| Drug | Propantheline bromide [50-34-0]; Up 200; 9uM; MCF7; HT_HG-U133A | 1.68e-05 | 200 | 166 | 9 | 3352_UP | |
| Drug | thioridazine hydrochloride; Up 200; 10uM; MCF7; HT_HG-U133A_EA | 1.96e-05 | 156 | 166 | 8 | 1010_UP | |
| Drug | Suloctidil [54063-56-8]; Up 200; 11.8uM; MCF7; HT_HG-U133A | 2.05e-05 | 157 | 166 | 8 | 2651_UP | |
| Drug | Pimozide [2062-78-4]; Up 200; 8.6uM; MCF7; HT_HG-U133A | 3.06e-05 | 166 | 166 | 8 | 6780_UP | |
| Drug | Gastrin tetrapeptide | 3.15e-05 | 50 | 166 | 5 | CID000005415 | |
| Drug | fullerene C60 | TCEA3 TCF4 ABL1 CEBPB ARHGAP10 PATZ1 GAS2 UBQLN4 SREBF1 TNIP1 LRRK1 SRCAP ZFP36 MAP3K1 FOXB1 AP2A1 BAZ2A ZMIZ2 PDE4DIP TIGD3 SDC3 BSN MUC6 MUC7 KAT14 WNK4 | 3.25e-05 | 1498 | 166 | 26 | ctd:C069837 |
| Drug | Puromycin dihydrochloride [58-58-2]; Up 200; 7.4uM; MCF7; HT_HG-U133A | 3.34e-05 | 168 | 166 | 8 | 5310_UP | |
| Drug | Emetine dihydrochloride [316-42-7]; Up 200; 7.2uM; MCF7; HT_HG-U133A | 3.34e-05 | 168 | 166 | 8 | 2801_UP | |
| Drug | trichostatin A, Streptomyces sp.; Up 200; 1uM; PC3; HT_HG-U133A | 4.11e-05 | 173 | 166 | 8 | 7077_UP | |
| Drug | Thonzonium bromide [553-08-2]; Up 200; 6.8uM; PC3; HT_HG-U133A | 4.11e-05 | 173 | 166 | 8 | 4617_UP | |
| Drug | Felodipine [72509-76-3]; Up 200; 10.4uM; MCF7; HT_HG-U133A | 4.46e-05 | 175 | 166 | 8 | 3295_UP | |
| Drug | mucic acid | 4.54e-05 | 88 | 166 | 6 | CID000000607 | |
| Drug | thioridazine hydrochloride; Up 200; 10uM; PC3; HT_HG-U133A | 4.83e-05 | 177 | 166 | 8 | 1230_UP | |
| Drug | (+)-Isoproterenol (+)-bitartrate salt [14638-70-1]; Up 200; 11uM; PC3; HT_HG-U133A | 5.88e-05 | 182 | 166 | 8 | 6663_UP | |
| Drug | Suloctidil [54063-56-8]; Up 200; 11.8uM; PC3; HT_HG-U133A | 6.86e-05 | 186 | 166 | 8 | 6675_UP | |
| Drug | Cloperastine hydrochloride [14984-68-0]; Up 200; 11uM; PC3; HT_HG-U133A | 6.86e-05 | 186 | 166 | 8 | 4271_UP | |
| Drug | 2-propylpentanoic acid; Up 200; 1000uM; MCF7; HT_HG-U133A_EA | 7.67e-05 | 189 | 166 | 8 | 989_UP | |
| Drug | CP-319743 [172078-87-4]; Up 200; 10uM; PC3; HT_HG-U133A | 7.67e-05 | 189 | 166 | 8 | 7537_UP | |
| Drug | celecoxib; Up 200; 10uM; MCF7; HT_HG-U133A_EA | 7.67e-05 | 189 | 166 | 8 | 922_UP | |
| Drug | 0179445-0000 [211246-22-9]; Up 200; 10uM; PC3; HT_HG-U133A | 7.96e-05 | 190 | 166 | 8 | 3733_UP | |
| Drug | Methotrexate [59-05-2]; Down 200; 8.8uM; PC3; HT_HG-U133A | 7.96e-05 | 190 | 166 | 8 | 6318_DN | |
| Drug | Mitoxantrone dihydrochloride [70476-82-3]; Up 200; 7.8uM; MCF7; HT_HG-U133A | 7.96e-05 | 190 | 166 | 8 | 3232_UP | |
| Drug | Hexestrol [84-16-2]; Up 200; 14.8uM; MCF7; HT_HG-U133A | 8.25e-05 | 191 | 166 | 8 | 6077_UP | |
| Drug | thapsigargin; Down 200; 0.1uM; MCF7; HT_HG-U133A | 8.25e-05 | 191 | 166 | 8 | 7100_DN | |
| Drug | vinblastine sulfate; Up 200; 0.1uM; PC3; HT_HG-U133A | 8.56e-05 | 192 | 166 | 8 | 7556_UP | |
| Drug | Dimethisoquin hydrochloride [2773-92-4]; Up 200; 13uM; MCF7; HT_HG-U133A | 8.56e-05 | 192 | 166 | 8 | 2807_UP | |
| Drug | SC 19220; Down 200; 10uM; PC3; HT_HG-U133A | 8.56e-05 | 192 | 166 | 8 | 7065_DN | |
| Drug | Galanthamine hydrobromide [1953-04-4]; Down 200; 10.8uM; PC3; HT_HG-U133A | 8.88e-05 | 193 | 166 | 8 | 4186_DN | |
| Drug | Ethacrynic acid [58-54-8]; Down 200; 13.2uM; MCF7; HT_HG-U133A | 8.88e-05 | 193 | 166 | 8 | 3181_DN | |
| Drug | 2-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester | HHEX ATG9B ARHGAP10 KIF26B GAS2 VIT NR3C1 PITPNC1 SNCAIP MICAL2 TIGD3 DISP2 MAFB CHD6 BSN WNK4 GAB1 | 8.91e-05 | 807 | 166 | 17 | ctd:C548651 |
| Drug | rosiglitazone maleate; Down 200; 10uM; PC3; HG-U133A | 9.20e-05 | 194 | 166 | 8 | 430_DN | |
| Drug | Betazole hydrochloride; Up 200; 27uM; PC3; HT_HG-U133A | 9.20e-05 | 194 | 166 | 8 | 1812_UP | |
| Drug | Amitryptiline hydrochloride [549-18-8]; Up 200; 12.8uM; PC3; HT_HG-U133A | 9.20e-05 | 194 | 166 | 8 | 1823_UP | |
| Drug | Methoxy-6-harmalan [3589-73-9]; Up 200; 18.6uM; MCF7; HT_HG-U133A | 9.20e-05 | 194 | 166 | 8 | 2893_UP | |
| Drug | Fludrocortisone acetate [514-36-3]; Down 200; 9.4uM; MCF7; HT_HG-U133A | 9.20e-05 | 194 | 166 | 8 | 3977_DN | |
| Drug | Dienestrol [84-17-3]; Up 200; 15uM; MCF7; HT_HG-U133A | 9.20e-05 | 194 | 166 | 8 | 6208_UP | |
| Drug | Florfenicol [73231-34-2]; Down 200; 11.2uM; PC3; HT_HG-U133A | 9.54e-05 | 195 | 166 | 8 | 6701_DN | |
| Drug | Xylazine [7361-61-7]; Down 200; 18.2uM; MCF7; HT_HG-U133A | 9.54e-05 | 195 | 166 | 8 | 4147_DN | |
| Drug | Pralidoxime chloride [51-15-0]; Down 200; 23.2uM; PC3; HT_HG-U133A | 9.54e-05 | 195 | 166 | 8 | 6283_DN | |
| Drug | Alfaxalone [23930-19-0]; Down 200; 12uM; MCF7; HT_HG-U133A | 9.54e-05 | 195 | 166 | 8 | 6514_DN | |
| Drug | 3-Acetylcoumarin [3949-36-8]; Down 200; 21.2uM; PC3; HT_HG-U133A | 9.54e-05 | 195 | 166 | 8 | 4664_DN | |
| Drug | 2-propylpentanoic acid; Up 200; 50uM; MCF7; HT_HG-U133A | 9.54e-05 | 195 | 166 | 8 | 5582_UP | |
| Drug | Amoxapine [14028-44-5]; Up 200; 12.8uM; PC3; HT_HG-U133A | 9.88e-05 | 196 | 166 | 8 | 6650_UP | |
| Drug | Meclofenamic acid sodium salt monohydrate [6385-02-0]; Up 200; 11.8uM; HL60; HG-U133A | 9.88e-05 | 196 | 166 | 8 | 1445_UP | |
| Drug | Sulfadimethoxine [122-11-2]; Up 200; 12.8uM; PC3; HT_HG-U133A | 9.88e-05 | 196 | 166 | 8 | 7400_UP | |
| Drug | Ampyrone [83-07-8]; Up 200; 19.6uM; PC3; HT_HG-U133A | 9.88e-05 | 196 | 166 | 8 | 2086_UP | |
| Drug | Betamethasone [378-44-9]; Down 200; 10.2uM; PC3; HT_HG-U133A | 9.88e-05 | 196 | 166 | 8 | 6728_DN | |
| Drug | Pentetic acid [67-43-6]; Up 200; 10.2uM; MCF7; HT_HG-U133A | 9.88e-05 | 196 | 166 | 8 | 3387_UP | |
| Drug | Iodipamide [606-17-7]; Up 200; 3.6uM; MCF7; HT_HG-U133A | 9.88e-05 | 196 | 166 | 8 | 5510_UP | |
| Drug | Retinoic acid [302-79-4]; Down 200; 13.4uM; PC3; HT_HG-U133A | 9.88e-05 | 196 | 166 | 8 | 5767_DN | |
| Drug | Flutamide [13311-84-7]; Down 200; 14.4uM; PC3; HT_HG-U133A | 9.88e-05 | 196 | 166 | 8 | 4539_DN | |
| Drug | Antimycin A [1397-94-0]; Up 200; 7.2uM; HL60; HG-U133A | 9.88e-05 | 196 | 166 | 8 | 1414_UP | |
| Drug | Fosfosal [6064-83-1]; Down 200; 18.4uM; HL60; HT_HG-U133A | 9.88e-05 | 196 | 166 | 8 | 2997_DN | |
| Drug | Eucatropine hydrochloride [536-93-6]; Up 200; 12.2uM; MCF7; HT_HG-U133A | 9.88e-05 | 196 | 166 | 8 | 3416_UP | |
| Drug | Cefotaxime sodium salt [64485-93-4]; Down 200; 8.4uM; PC3; HT_HG-U133A | 9.88e-05 | 196 | 166 | 8 | 5830_DN | |
| Drug | Fenofibrate [49562-28-9]; Up 200; 11uM; MCF7; HT_HG-U133A | 9.88e-05 | 196 | 166 | 8 | 7432_UP | |
| Drug | Metoprolol-(+,-) (+)-tartrate salt [56392-17-7]; Down 200; 5.8uM; MCF7; HT_HG-U133A | 1.02e-04 | 197 | 166 | 8 | 6106_DN | |
| Drug | Trimethylcolchicinic acid [3482-37-9]; Down 200; 11.6uM; MCF7; HT_HG-U133A | 1.02e-04 | 197 | 166 | 8 | 4787_DN | |
| Drug | Carbimazole [22232-54-8]; Up 200; 21.4uM; MCF7; HT_HG-U133A | 1.02e-04 | 197 | 166 | 8 | 3299_UP | |
| Drug | Naproxen [22204-53-1]; Down 200; 17.4uM; PC3; HT_HG-U133A | 1.02e-04 | 197 | 166 | 8 | 1828_DN | |
| Drug | Scopolamin-N-oxide hydrobromide [6106-81-6]; Up 200; 10uM; PC3; HT_HG-U133A | 1.02e-04 | 197 | 166 | 8 | 6335_UP | |
| Drug | LY 294002; Up 200; 0.1uM; PC3; HT_HG-U133A | 1.02e-04 | 197 | 166 | 8 | 1216_UP | |
| Drug | Diethylcarbamazine citrate [1642-54-2]; Down 200; 10.2uM; MCF7; HT_HG-U133A | 1.02e-04 | 197 | 166 | 8 | 7425_DN | |
| Drug | Seneciphylline [480-81-9]; Up 200; 12uM; MCF7; HT_HG-U133A | 1.02e-04 | 197 | 166 | 8 | 4822_UP | |
| Drug | Promethazine hydrochloride [58-33-3]; Up 200; 12.4uM; MCF7; HT_HG-U133A | 1.02e-04 | 197 | 166 | 8 | 5317_UP | |
| Drug | Retinoic acid [302-79-4]; Down 200; 13.4uM; MCF7; HT_HG-U133A | 1.02e-04 | 197 | 166 | 8 | 3165_DN | |
| Drug | Selegiline hydrochloride [14611-52-0]; Up 200; 17.8uM; MCF7; HT_HG-U133A | 1.02e-04 | 197 | 166 | 8 | 2826_UP | |
| Drug | Pentolinium bitartrate [52-62-0]; Down 200; 7.4uM; MCF7; HT_HG-U133A | 1.02e-04 | 197 | 166 | 8 | 4699_DN | |
| Disease | mucinous adenocarcinoma (is_marker_for) | 4.69e-09 | 5 | 165 | 4 | DOID:3030 (is_marker_for) | |
| Disease | cholangiocarcinoma (is_marker_for) | 1.60e-06 | 64 | 165 | 6 | DOID:4947 (is_marker_for) | |
| Disease | obesity (implicated_via_orthology) | 3.67e-06 | 215 | 165 | 9 | DOID:9970 (implicated_via_orthology) | |
| Disease | cortical thickness | TCF4 NYAP2 CHAF1A SREBF1 FNBP1L VIT IRAG1 RFX4 PXK MAP3K1 GRIP1 ZNF469 ARHGEF40 NALF1 MEGF9 TOX3 KCTD3 DOCK7 KMT2A ELL | 4.46e-06 | 1113 | 165 | 20 | EFO_0004840 |
| Disease | respiratory system disease | 1.82e-05 | 145 | 165 | 7 | EFO_0000684 | |
| Disease | cortical surface area measurement | TET2 TCF4 NYAP2 KIF26B CHAF1A SREBF1 FNBP1L MED13L IRAG1 RFX4 MAP3K1 GRIP1 EVI5 CCDC88C MSX2 ZNF469 NALF1 PRRC2C TOX3 ZFHX3 NOVA1 | 2.13e-05 | 1345 | 165 | 21 | EFO_0010736 |
| Disease | cystitis (is_marker_for) | 3.11e-05 | 2 | 165 | 2 | DOID:1679 (is_marker_for) | |
| Disease | lipid storage disease (biomarker_via_orthology) | 3.11e-05 | 2 | 165 | 2 | DOID:9455 (biomarker_via_orthology) | |
| Disease | testosterone measurement | TET2 HHEX NYAP2 ARHGAP10 ZBTB4 UBQLN4 ANKS1B NR3C1 SRCAP EVI5 ARHGEF40 SLC2A4RG NALF1 EGR1 AGFG2 JAZF1 MAFB ZFHX3 MED12 MAF | 3.18e-05 | 1275 | 165 | 20 | EFO_0004908 |
| Disease | hematocrit | NYAP2 UBAP2 ARHGAP10 CHAF1A UBQLN4 SREBF1 NR3C1 IRAG1 PXK ARHGEF40 MIDN ZMIZ2 TOX3 AGFG2 PLCB3 BSN ELL | 5.56e-05 | 1011 | 165 | 17 | EFO_0004348 |
| Disease | glucose measurement | 5.94e-05 | 380 | 165 | 10 | EFO_0004468 | |
| Disease | sputum mucin-5B amount | 9.29e-05 | 3 | 165 | 2 | OBA_2050332 | |
| Disease | angiopoietin-related protein 3 measurement | 9.29e-05 | 3 | 165 | 2 | EFO_0020148 | |
| Disease | keratoconjunctivitis (is_marker_for) | 9.29e-05 | 3 | 165 | 2 | DOID:9368 (is_marker_for) | |
| Disease | heart rate response to exercise | 9.81e-05 | 43 | 165 | 4 | EFO_0009184 | |
| Disease | neuroimaging measurement | TCF4 UBAP2 KIF26B CHAF1A PAK5 IRAG1 POM121C MAP3K1 CCDC88C MSX2 ZNF469 NALF1 SBNO1 PRRC2C TOX3 MAF INO80E | 1.09e-04 | 1069 | 165 | 17 | EFO_0004346 |
| Disease | Neurodevelopmental Disorders | 1.80e-04 | 93 | 165 | 5 | C1535926 | |
| Disease | Prostatic Neoplasms | TET2 TOM1L1 NR3C1 MAP3K1 WAC EGR1 BAZ2A JAZF1 KMT2A ZFHX3 CHD6 MED12 | 1.92e-04 | 616 | 165 | 12 | C0033578 |
| Disease | Malignant neoplasm of prostate | TET2 TOM1L1 NR3C1 MAP3K1 WAC EGR1 BAZ2A JAZF1 KMT2A ZFHX3 CHD6 MED12 | 1.92e-04 | 616 | 165 | 12 | C0376358 |
| Disease | Paroxysmal atrial fibrillation | 2.54e-04 | 156 | 165 | 6 | C0235480 | |
| Disease | familial atrial fibrillation | 2.54e-04 | 156 | 165 | 6 | C3468561 | |
| Disease | Persistent atrial fibrillation | 2.54e-04 | 156 | 165 | 6 | C2585653 | |
| Disease | Psychotic Disorders | 2.64e-04 | 101 | 165 | 5 | C0033975 | |
| Disease | Atrial Fibrillation | 2.91e-04 | 160 | 165 | 6 | C0004238 | |
| Disease | apolipoprotein A 1 measurement | TET2 TCEA3 NYAP2 RFX4 SLC2A4RG SBNO1 MUC17 ZMIZ2 DOCK7 KMT2A PLCB3 HERC1 USP1 ELL | 3.10e-04 | 848 | 165 | 14 | EFO_0004614 |
| Disease | Libman-Sacks Disease | 3.16e-04 | 58 | 165 | 4 | C0242380 | |
| Disease | chylomicron measurement, very low density lipoprotein cholesterol measurement | 3.31e-04 | 106 | 165 | 5 | EFO_0008317, EFO_0008596 | |
| Disease | prostate carcinoma, type 2 diabetes mellitus | 3.38e-04 | 59 | 165 | 4 | EFO_0001663, MONDO_0005148 | |
| Disease | cholesterol in chylomicrons and extremely large VLDL measurement | 3.60e-04 | 60 | 165 | 4 | EFO_0021898 | |
| Disease | chylomicron measurement, very low density lipoprotein cholesterol measurement, phospholipid measurement | 3.76e-04 | 109 | 165 | 5 | EFO_0004639, EFO_0008317, EFO_0008596 | |
| Disease | lymphocyte percentage of leukocytes | TET2 NYAP2 TNIP1 LRRK1 NR3C1 AATK SBNO1 JAZF1 MAFB PLCB3 NEURL1B ELL | 3.83e-04 | 665 | 165 | 12 | EFO_0007993 |
| Disease | free cholesterol in very large VLDL measurement | 3.84e-04 | 61 | 165 | 4 | EFO_0022274 | |
| Disease | cholesteryl ester measurement, chylomicron measurement, very low density lipoprotein cholesterol measurement | 3.92e-04 | 110 | 165 | 5 | EFO_0008317, EFO_0008596, EFO_0010351 | |
| Disease | free cholesterol measurement, chylomicron measurement, very low density lipoprotein cholesterol measurement | 3.92e-04 | 110 | 165 | 5 | EFO_0008317, EFO_0008591, EFO_0008596 | |
| Disease | chylomicron measurement, total cholesterol measurement, very low density lipoprotein cholesterol measurement | 3.92e-04 | 110 | 165 | 5 | EFO_0004574, EFO_0008317, EFO_0008596 | |
| Disease | systemic scleroderma, systemic lupus erythematosus | 4.06e-04 | 26 | 165 | 3 | EFO_0000717, MONDO_0007915 | |
| Disease | free cholesterol in chylomicrons and extremely large VLDL measurement | 4.09e-04 | 62 | 165 | 4 | EFO_0022263 | |
| Disease | phospholipids in very large VLDL measurement | 4.09e-04 | 62 | 165 | 4 | EFO_0022299 | |
| Disease | prostate carcinoma, breast carcinoma, ovarian carcinoma | 4.55e-04 | 27 | 165 | 3 | EFO_0000305, EFO_0001075, EFO_0001663 | |
| Disease | insulin measurement, glucose tolerance test | 4.59e-04 | 6 | 165 | 2 | EFO_0004307, EFO_0004467 | |
| Disease | multiple sclerosis | TET2 NR3C1 EVI5 USP31 SLC2A4RG MCTP1 JAZF1 ZFHX3 TNFAIP3 TOX2 MAF | 5.42e-04 | 594 | 165 | 11 | MONDO_0005301 |
| Disease | triglycerides in very small VLDL measurement | 5.81e-04 | 68 | 165 | 4 | EFO_0022144 | |
| Disease | triglycerides to phosphoglycerides ratio | 5.81e-04 | 68 | 165 | 4 | EFO_0022327 | |
| Disease | Nonorganic psychosis | 6.14e-04 | 69 | 165 | 4 | C0349204 | |
| Disease | breast cancer (is_marker_for) | 6.28e-04 | 185 | 165 | 6 | DOID:1612 (is_marker_for) | |
| Disease | Intrahepatic Cholestasis | 6.41e-04 | 7 | 165 | 2 | C0008372 | |
| Disease | Lupus Erythematosus, Systemic | 6.84e-04 | 71 | 165 | 4 | C0024141 | |
| Disease | eosinophil count | TET2 HHEX PATZ1 SREBF1 TNIP1 SEC31A NR3C1 WAC SDC3 MAFB PLCB3 TNFAIP3 NEURL1B CORO7 MUC2 TOX2 MUC5AC MAST3 MAF | 6.87e-04 | 1488 | 165 | 19 | EFO_0004842 |
| Disease | docosahexaenoic acid measurement | 7.55e-04 | 127 | 165 | 5 | EFO_0007761 | |
| Disease | psoriasis, type 2 diabetes mellitus | 8.41e-04 | 75 | 165 | 4 | EFO_0000676, MONDO_0005148 | |
| Disease | calcium measurement | TET2 TCEA3 HHEX SREBF1 IRAG1 PPP4R4 MAFB ZFHX3 NEURL1B TOX2 PARM1 | 8.55e-04 | 628 | 165 | 11 | EFO_0004838 |
| Disease | complex trait | 8.64e-04 | 271 | 165 | 7 | EFO_0010578 | |
| Disease | monounsaturated fatty acids; 16:1, 18:1 measurement | 9.75e-04 | 78 | 165 | 4 | EFO_0022187 | |
| Disease | bringing up phlegm, sputum or mucus on most days, self-reported | 1.09e-03 | 9 | 165 | 2 | EFO_0009824 | |
| Disease | chronic central serous retinopathy | 1.09e-03 | 9 | 165 | 2 | EFO_0009363 | |
| Disease | 1-palmitoyl-2-oleoyl-GPI (16:0/18:1) measurement | 1.09e-03 | 9 | 165 | 2 | EFO_0800439 | |
| Disease | brain measurement, neuroimaging measurement | TCF4 KIF26B RFX4 MAP3K1 CCDC88C MCTP1 SBNO1 TOX3 SUGP1 ZFHX3 | 1.11e-03 | 550 | 165 | 10 | EFO_0004346, EFO_0004464 |
| Disease | C-reactive protein measurement | TCF4 UBE4B ARHGAP10 TNIP1 FNBP1L VIT MAP3K1 ZNF469 SBNO1 ZMIZ2 DOCK7 JAZF1 MAFB NEURL1B BSN PDLIM2 | 1.24e-03 | 1206 | 165 | 16 | EFO_0004458 |
| Disease | systemic scleroderma, rheumatoid arthritis, myositis, systemic lupus erythematosus | 1.25e-03 | 38 | 165 | 3 | EFO_0000685, EFO_0000717, EFO_0000783, MONDO_0007915 | |
| Disease | free androgen index | 1.26e-03 | 374 | 165 | 8 | EFO_0007005 | |
| Disease | response to bronchodilator, FEV/FEC ratio | TET2 TCF4 NRL TUT1 FNBP1L PPP4R4 GRIP1 MCTP1 ZFHX3 PKN1 TOX2 MAF | 1.31e-03 | 766 | 165 | 12 | EFO_0004713, GO_0097366 |
| Disease | dry eye syndrome (is_marker_for) | 1.36e-03 | 10 | 165 | 2 | DOID:10140 (is_marker_for) | |
| Disease | lymphocyte count | TET2 TCF4 NYAP2 ABL1 UBAP2 UBE4B RTN4 SREBF1 TNIP1 MED13L SPATA32 RSBN1 ZNF469 SBNO1 JAZF1 MAFB NEURL1B CORO7 | 1.46e-03 | 1464 | 165 | 18 | EFO_0004587 |
| Disease | obsolete_red blood cell distribution width | NYAP2 ABL1 PATZ1 CHAF1A RTN4 MAP3K1 KSR1 MUC17 PRRC2C SIMC1 MAFB NEURL1B HERC1 TOX2 ELL MAST3 BORA | 1.50e-03 | 1347 | 165 | 17 | EFO_0005192 |
| Disease | resting heart rate | 1.54e-03 | 149 | 165 | 5 | EFO_0004351 | |
| Disease | visual epilepsy (biomarker_via_orthology) | 1.66e-03 | 90 | 165 | 4 | DOID:11832 (biomarker_via_orthology) | |
| Disease | cancer | 1.93e-03 | 400 | 165 | 8 | MONDO_0004992 | |
| Disease | protein CEI measurement | 1.98e-03 | 12 | 165 | 2 | EFO_0801936 | |
| Disease | event free survival time, type 1 diabetes mellitus, autoantibody measurement | 1.98e-03 | 12 | 165 | 2 | EFO_0000482, EFO_0004866, MONDO_0005147 | |
| Disease | chylomicron measurement, very low density lipoprotein cholesterol measurement, lipid measurement | 2.02e-03 | 95 | 165 | 4 | EFO_0004529, EFO_0008317, EFO_0008596 | |
| Disease | total lipids in very small VLDL measurement | 2.05e-03 | 45 | 165 | 3 | EFO_0022156 | |
| Disease | saturated fatty acids measurement | 2.05e-03 | 45 | 165 | 3 | EFO_0022304 | |
| Disease | Inhalant adrenergic use measurement | 2.10e-03 | 96 | 165 | 4 | EFO_0009941 | |
| Disease | chylomicron measurement, triglyceride measurement, very low density lipoprotein cholesterol measurement | 2.10e-03 | 96 | 165 | 4 | EFO_0004530, EFO_0008317, EFO_0008596 | |
| Disease | free cholesterol in very small VLDL measurement | 2.32e-03 | 47 | 165 | 3 | EFO_0022275 | |
| Disease | Sjogren's Syndrome | 2.33e-03 | 13 | 165 | 2 | C1527336 | |
| Disease | level of Phosphatidylinositol (18:1_18:1) in blood serum | 2.33e-03 | 13 | 165 | 2 | OBA_2045159 | |
| Disease | Sicca Syndrome | 2.33e-03 | 13 | 165 | 2 | C0086981 | |
| Disease | uric acid measurement | 2.37e-03 | 610 | 165 | 10 | EFO_0004761 | |
| Disease | triglyceride measurement, low density lipoprotein cholesterol measurement | 2.47e-03 | 166 | 165 | 5 | EFO_0004530, EFO_0004611 | |
| Disease | attention deficit hyperactivity disorder, unipolar depression, bipolar disorder, autism spectrum disorder, schizophrenia | 2.53e-03 | 101 | 165 | 4 | EFO_0003756, EFO_0003761, EFO_0003888, MONDO_0004985, MONDO_0005090 | |
| Disease | lung non-small cell carcinoma (is_marker_for) | 2.67e-03 | 169 | 165 | 5 | DOID:3908 (is_marker_for) | |
| Disease | gastric ulcer (implicated_via_orthology) | 2.71e-03 | 14 | 165 | 2 | DOID:10808 (implicated_via_orthology) | |
| Disease | lipoprotein measurement | 2.91e-03 | 105 | 165 | 4 | EFO_0004732 | |
| Disease | phospholipids in very small VLDL measurement | 2.94e-03 | 51 | 165 | 3 | EFO_0022300 | |
| Disease | familial hyperlipidemia | 3.01e-03 | 106 | 165 | 4 | MONDO_0001336 | |
| Disease | blood phosphate measurement | 3.02e-03 | 174 | 165 | 5 | EFO_0010972 | |
| Disease | monocyte count | TET2 TCF4 NYAP2 CEBPB TRPM7 MED13L IRAG1 EVI5 RSBN1 KSR1 ZMIZ2 JAZF1 MAFB NEURL1B CABIN1 ELL | 3.08e-03 | 1320 | 165 | 16 | EFO_0005091 |
| Disease | myelodysplastic syndrome (implicated_via_orthology) | 3.11e-03 | 15 | 165 | 2 | DOID:0050908 (implicated_via_orthology) | |
| Disease | fatty acid measurement | 3.27e-03 | 436 | 165 | 8 | EFO_0005110 | |
| Disease | total phospholipids in lipoprotein particles measurement | 3.28e-03 | 53 | 165 | 3 | EFO_0022315 | |
| Disease | eosinophil percentage of leukocytes | TCEA3 PATZ1 TNIP1 NR3C1 TNFAIP3 NEURL1B MUC2 TOX2 MUC5AC MAST3 MAF | 3.29e-03 | 746 | 165 | 11 | EFO_0007991 |
| Disease | Metastatic melanoma | 3.46e-03 | 54 | 165 | 3 | C0278883 | |
| Disease | cutaneous psoriasis measurement, psoriasis | 3.54e-03 | 16 | 165 | 2 | EFO_0000676, EFO_0007773 | |
| Disease | body mass index, type 2 diabetes mellitus | 3.54e-03 | 16 | 165 | 2 | EFO_0004340, MONDO_0005148 | |
| Disease | triglyceride measurement, intermediate density lipoprotein measurement | 3.55e-03 | 111 | 165 | 4 | EFO_0004530, EFO_0008595 | |
| Disease | non-alcoholic fatty liver disease | 3.66e-03 | 182 | 165 | 5 | EFO_0003095 | |
| Disease | severe acute respiratory syndrome, COVID-19 | 3.79e-03 | 447 | 165 | 8 | EFO_0000694, MONDO_0100096 | |
| Disease | sexual dimorphism measurement | TET2 NYAP2 RTN4 ZBTB4 NR3C1 FAM83C ARHGEF40 JAZF1 ZFHX3 PLCB3 HERC1 BSN NPAS4 NPAS1 | 3.80e-03 | 1106 | 165 | 14 | EFO_0021796 |
| Disease | triglycerides in LDL measurement | 3.83e-03 | 56 | 165 | 3 | EFO_0022320 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| PSVSRSTSPPTEAPF | 116 | A8MUN3 | |
| STFSAPLPSPRTATP | 206 | O75871 | |
| LPTPGPPASTDTLSS | 366 | P55199 | |
| SPSLSSLLLPSSPGP | 986 | Q8TER5 | |
| TPTTFLSPTEPTLPF | 1641 | Q8IZF6 | |
| PSAGPATSPPLSTTT | 401 | O94910 | |
| SPVTSPAAAFPTASP | 496 | Q9UIF9 | |
| SQSPTSPASSSPKPG | 316 | Q9UK96 | |
| PTPSTVSTPSPSADL | 646 | O95782 | |
| LPPPPTSALSSIAST | 846 | Q8IY63 | |
| TSISEPPSPISPYAS | 616 | Q9NZJ0 | |
| SLSSPSSTSSPEGPP | 286 | Q13111 | |
| PSSSSGPPPTTSTLQ | 66 | A7MBM2 | |
| AITSPLPANTPSPSF | 531 | Q5T6C5 | |
| ASPTAAPESSTSFPP | 91 | P54725 | |
| TPSPVPSFSPAKSAT | 506 | Q33E94 | |
| GPPTPPSVSSSSSSS | 206 | Q99742 | |
| SFSPPTGPSPSLAQS | 191 | P22736 | |
| CTSFTASPPASPPTS | 556 | Q7Z6G8 | |
| LSSLSLSSSTYPPPS | 401 | Q9P286 | |
| AVTPLSPGSSPFPFS | 701 | A1A4S6 | |
| SSTSPESIPSSPLPV | 5646 | Q8WXI7 | |
| SLPATTSPPPISSTL | 7101 | Q8WXI7 | |
| TNSATSSRPPPPFTT | 1561 | Q6W4X9 | |
| PLAPRGTPTSFSSSS | 456 | A5PL33 | |
| SASSSLSSSPQPPPR | 161 | Q6DN14 | |
| AGPSSSSSLPPPASS | 451 | Q71F56 | |
| STPCSSVPSSPSFSP | 61 | Q9Y5Q3 | |
| PPGSLSSTPLSTPCS | 46 | Q8NHW3 | |
| STPCSSVPPSPSFSA | 61 | O75444 | |
| SLPPTSNAPSDPATT | 386 | Q9H8Y8 | |
| APFRSPTAPSVFSPT | 221 | Q9H3P2 | |
| EPALPSTSYLPSTPS | 316 | Q9H3P2 | |
| PSTPSVVPASSYIPS | 326 | Q9H3P2 | |
| PPAASVISAPPSSSS | 346 | Q7L2J0 | |
| PPSDTPIPFSSSSTH | 6 | Q86W28 | |
| PSSLPSSPASSSSVP | 1856 | Q38SD2 | |
| TPAPTLPSPNSSFTS | 46 | Q03014 | |
| PPSTQADSSSATLPP | 146 | Q13480 | |
| PDSTPATSTAAPSAP | 166 | O43561 | |
| FSSNPSTPVGSPPSL | 341 | P15884 | |
| SPSPASPRSVPGSSS | 1016 | Q2KJY2 | |
| SRSPGLSPSSPSPEF | 441 | Q86X51 | |
| ALSDPSSRLSTSPPP | 2736 | Q15751 | |
| PVTPPITPSSSFRSS | 111 | Q86VZ6 | |
| SYFASSSPPLSPSSP | 1471 | Q9UPA5 | |
| SPSSPSESPTFSPGK | 1481 | Q9UPA5 | |
| PSPIKSSSADSTPSP | 226 | Q9P219 | |
| PPSSLTSPSTPSSLG | 431 | P57737 | |
| PSPVTTSYPSPATTS | 451 | P18146 | |
| PATTSYPSPVPTSFS | 461 | P18146 | |
| PSPSVATTYSSVPPA | 491 | P18146 | |
| PSAVSPNLSPSASPT | 181 | Q9Y6F6 | |
| TTSSTPSSPAPFPTS | 451 | Q8IVT5 | |
| PSSPAPFPTSSNPSS | 456 | Q8IVT5 | |
| TPPTFSPFSTTTPTT | 1766 | Q02817 | |
| SPFSTTTPTTPCVPL | 1771 | Q02817 | |
| TSPPTTPLTVFPFTT | 2796 | Q02505 | |
| STPALSPSSPSQLSP | 66 | O60447 | |
| SSSDRTPLTSPSPSP | 316 | Q9H8E8 | |
| TPLTSPSPSPSLDFS | 321 | Q9H8E8 | |
| STPYSSVPPSPTFSE | 41 | P54845 | |
| CPPLTLTFSPDSSTP | 1321 | Q7Z7M0 | |
| LPPFSALVSSPSLSP | 766 | Q9UQ05 | |
| PSSTTFQAPLGPSPT | 111 | Q9H1U4 | |
| PPTSSTPSTPFSDLL | 336 | Q93074 | |
| PSSSSTATTGPPPKL | 406 | P04150 | |
| TLSPPSTASFSLSPF | 401 | Q3SXY7 | |
| LPPAPATSPSISTSE | 4831 | P98088 | |
| SSSSSSSGPPLPLPS | 666 | Q9ULI3 | |
| PSPLPVSLTTSTSAP | 716 | Q9ULI3 | |
| SSSPPPPSTLYRTQS | 411 | Q9P242 | |
| PTLISPQAPASSPSS | 146 | Q6UWI2 | |
| PQAPASSPSSLSTSP | 151 | Q6UWI2 | |
| SSPSPSLSSSVLPPS | 46 | Q8TDS5 | |
| SLSSSVLPPSFSPSP | 51 | Q8TDS5 | |
| PTLLSNSPPSLSPTS | 281 | Q99853 | |
| SPSSLSLPPSTGFPL | 106 | Q8NBZ0 | |
| TPPGPSVSATAPSSS | 721 | A8CG34 | |
| LLPSPSFDSNPPTTL | 231 | A6NF01 | |
| PATLPATSSSLPSPA | 266 | P35227 | |
| LLTSPFPSVASSAPP | 246 | Q9HBE1 | |
| PGPTTSPASTSLSSP | 921 | Q01970 | |
| PPTPSATTLDPSSAS | 261 | Q8TAX7 | |
| TPSSATFPDPLTSPL | 471 | Q8IUM7 | |
| SPLISSSSPSSPASP | 1651 | Q9Y2F5 | |
| NFPPPSSPTLSVSST | 626 | Q6TDP4 | |
| PLSSPPTAASSKAPS | 2091 | Q9Y6J0 | |
| PPASTLSPNPTSSTE | 211 | A6NFR6 | |
| LTPPASPSPSVSSAT | 1141 | Q96N67 | |
| PQSPPLTPTSLFTSS | 331 | Q5T0N5 | |
| TGSPSKISPPSTPSS | 446 | Q9ULE3 | |
| SPGATSPFPVSASTP | 2226 | Q8TD26 | |
| PPPPSSFSLTVLFDT | 301 | Q96MA1 | |
| FRPDVPSPTSSLPSS | 331 | Q9BQN1 | |
| ITSPSPISSPTFSPI | 266 | Q6PGQ7 | |
| TSSSSSPPGTPSPAD | 226 | P17676 | |
| PPTPATPTSSASNLD | 96 | Q7Z7K6 | |
| ISPAPVPSTLPSASS | 976 | P00519 | |
| APHTRSSPSSFSPPT | 56 | Q674R7 | |
| SPPSASPSSSSPASP | 1136 | O60307 | |
| SAPAEPFSSSSPTPL | 821 | Q03164 | |
| TLPVSSDASSPSPPA | 341 | Q8N9H9 | |
| PNSPPALVSSSFSPT | 396 | Q9Y3R0 | |
| ATPSTPAAPPFTATT | 186 | O75056 | |
| FSSTPVISPAPNSTP | 816 | A3KN83 | |
| SPGTASPSPTKTTPS | 786 | Q9Y597 | |
| LPSPDPAASSSPSTV | 906 | O94851 | |
| SSSSSSSPSPPPLSA | 1066 | Q13029 | |
| LPSSPTTTKSSPSDP | 151 | P51513 | |
| FPPAHSSTPPTTSAS | 4066 | Q685J3 | |
| SPPTTPLTVFPFTTE | 711 | Q9H195 | |
| LPSSFSLPFPISSPL | 216 | P35548 | |
| PALSTPSSSTPSVPA | 981 | Q13233 | |
| TSPSPASPSPITAGS | 206 | Q504T8 | |
| EETLSAPSPSPSPSS | 176 | O43903 | |
| SPVSSTVPAPSPLSA | 111 | Q9NQC3 | |
| PLPAPSTSALFTFSP | 161 | Q5VWQ0 | |
| STATTAPPSTAPSGP | 586 | P49848 | |
| ATPTTSAPSAPPASS | 446 | Q8N1F8 | |
| TASSPSSSPSPSPGS | 6 | P30872 | |
| SSNPPTSVPTAPALS | 171 | O75674 | |
| SSVPSSFSPNTPLPS | 826 | Q6NUP7 | |
| PAPFSRFTVSPAPTS | 1331 | Q6ZMQ8 | |
| LGPLSSSPLATPSPS | 296 | Q9H6K5 | |
| SAPLPPSTSASVPAS | 1751 | Q9Y520 | |
| FSRPLGPPSSSSISS | 1956 | Q14524 | |
| GPPSSSSISSTSFPP | 1961 | Q14524 | |
| PPTTSSQAPSPLLSS | 216 | Q96LK8 | |
| QPPPAAATTSSTSLP | 621 | Q8N196 | |
| LSSPSCSPSPQSETP | 371 | Q8NDZ2 | |
| PASPPLSSTSPTTAA | 291 | Q9NR46 | |
| SLPSSPSSPSSPASR | 556 | Q9Y6H5 | |
| PPRSAPSSDSSPSFV | 141 | Q8IZD0 | |
| PTATPSTVPSSPFTL | 256 | Q9BTA9 | |
| SSRDPPSSPSSLSSP | 566 | Q16512 | |
| PSVSPSVSDAFLPPS | 3831 | Q9P2P6 | |
| SSSQTPSTDPFPGSP | 266 | Q6P9B9 | |
| PSSTPSTTPAPTGLS | 1276 | Q6ZRS2 | |
| PIPNSSPLASPVSST | 1416 | Q6ZRS2 | |
| SSSSSSSPPLPLPSC | 226 | Q9NUC0 | |
| PSLPSSTSSSLPTGP | 16 | Q13278 | |
| RAGSPFSPPPSSSSL | 131 | Q96JY6 | |
| PPPSSPTLSAAASAT | 36 | O94993 | |
| TSSPGSLSPPPATLS | 66 | P36956 | |
| IASPPSSPSSSGTPA | 266 | Q96AP0 | |
| TPSSPLQSCTPSLSP | 336 | Q96AP0 | |
| SSSPFASKPPTTNPF | 466 | O95081 | |
| TSTDAPTSAPSAPPS | 101 | Q8IWZ8 | |
| SLPPATTCPASSTPA | 346 | Q8IWZ8 | |
| ALSIQTPPSSPPTAF | 426 | Q15025 | |
| PLAASSTTPPLPSSV | 286 | Q6B0B8 | |
| TGPPSALPSVSSLPS | 661 | Q5T6F2 | |
| PESSASIVTSYPPPS | 176 | Q9UPR6 | |
| LLGSSSDSLPTSPPP | 696 | Q9C0A1 | |
| PPTAPSPFLFSETTA | 461 | P21580 | |
| LASDQSSPSTPSPPL | 161 | Q9NR83 | |
| QPSSPSSLLSATPIP | 596 | Q9H6E5 | |
| ILSSSPSPPALASSP | 346 | O95155 | |
| PSSSPLPAPGSLTST | 81 | Q99469 | |
| TLPSFSPSAASPQAP | 96 | Q12772 | |
| ESSLVTAPSSPLSPP | 471 | A8MQ27 | |
| APSSAPSTPLSTDAP | 271 | Q9UKF7 | |
| PSLSSSSFSPSSSPP | 206 | P26651 | |
| TPTTLPRPSPSAAST | 196 | Q6UXI7 | |
| SSSSSSPPPASPPAS | 106 | Q9P1Z0 | |
| SGASSPLTSPSSPTP | 491 | Q7Z7A4 | |
| SSPTPPSTSGISALP | 501 | Q7Z7A4 | |
| AESPKTPSSPLTPTF | 156 | O75764 | |
| SPPASKSATPSPSSS | 201 | O15405 | |
| PISDPASSVSSSPSP | 141 | P50616 | |
| FPPTTPSTPTLAEFT | 761 | Q8NF64 | |
| ASPSESPLPSPATNT | 586 | Q96JG9 | |
| SPFSSFSDIPTISPP | 306 | Q9BXU3 | |
| SPPGSKSATPSPSSS | 201 | Q96NM4 | |
| PAAPSSPSSPSSARS | 46 | Q70CQ4 | |
| QASSPTSSPATSFPP | 931 | O94979 | |
| SFSATTTPPPPSQLL | 391 | Q6N021 | |
| ASSPSTPDPASAPST | 96 | Q9NRR5 | |
| PEAPTSSPATPATSS | 511 | Q9NRR5 | |
| SPPGSKSATPSPSSS | 206 | O94900 | |
| PHPTSSPLPFSSSTP | 856 | Q96J92 | |
| SPPTKFFVSTPSQPS | 1396 | Q96QT4 | |
| SLSPSTSPTSTPYLL | 766 | O94782 | |
| SFSSSPSPSPTPSPH | 601 | Q86VM9 | |
| AAKPPSFPPLSSSST | 3626 | Q15911 | |
| SSDTTPSPPGTTAAP | 3146 | Q9UKN1 | |
| RLLSASSSPTLPPSP | 121 | B1AL88 | |
| LPSAPSSFLPFSPTG | 1711 | Q5VU43 |